Fluorescent protein sensors for measuring the pH of a biological sample

ABSTRACT

Disclosed are fluorescent protein sensors for measuring the pH of a sample, nucleic acids encoding them, and methods of use. The preferred fluorescent protein sensors are variants of the green fluorescent protein (GFP) from Aequorea victoria. Also disclosed are compositions and methods for measuring the pH of a specific region of a cell, such as the mitochondrial matrix or the Golgi lumen.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

This invention was made with Government support under Grant No. NS27177, awarded by the National Institutes of Health. The Government may have rights in this invention.

FIELD OF THE INVENTION

The invention relates generally to compositions and methods for measuring the pH of a sample and more particularly to fluorescent protein sensors for measuring the pH of a biological sample.

BACKGROUND OF THE INVENTION

The pH within various cellular compartments is regulated to provide for the optimal activity of many cellular processes. In the secretory pathway, posttranslational processing of secretory proteins, the cleavage of prohormones, and the retrieval of escaped luminal endoplasmic reticulum proteins are all pH-dependent.

Several techniques have been described for measuring intracellular pH. Commonly used synthetic pH indicators can be localized to the cytosol and nucleus, but not selectively in organelles other than those in the endocytotic pathway. In addition, some cells are resistant to loading with cell-permeant dyes because of physical barriers such as the cell wall in bacteria, yeast, and plants, or the thickness of a tissue preparation such as brain slices.

Several methods have been described for measuring pH in specific regions of the cell. One technique uses microinjection of fluorescent indicators enclosed in liposomes. Once inside the cell, the liposomes fuse with vesicles in the trans-Golgi, and the pH of the intracellular compartments is determined by observing the fluorescence of the indicator. This procedure can be laborious, and the fluorescence of the indicator can be diminished due to leakage of the fluorescent indicator from the Golgi, or flux of the fluorescent indicator out of the Golgi as part of the secretory traffic in the Golgi pathway. In addition, the fusion of the liposomes and components of the Golgi must take place at 37° C.; however, this temperature facilitates leakage and flux of the fluorescent indicator from the Golgi.

A second method for measuring pH utilizes retrograde transport of fluorescein-labeled verotoxin 1B, which stains the entire Golgi complex en route to the endoplasmic reticulum. This method can be used, however, only in cells bearing the receptor globotriaosyl ceramide on the plasma membrane, and it may be limited by the residence time of the verotoxin in transit through the Golgi.

In a third method, intracellular pH has been measured using the chimeric protein CD25-TGN38, which cycles between the trans-Golgi network and the plasma membrane. At the plasma membrane, the CD25-motif binds extra-cellular anti-CD25 antibodies conjugated with a pH-sensitive fluorophore. Measurement of fluorescence upon return of the bound complex to the Golgi can be used to measure the pH of the organelle.

SUMMARY OF THE INVENTION

The invention is based on the discovery that proteins derived from the Aequorea victoria green fluorescence protein (GFP) show reversible changes in fluorescence over physiological pH ranges.

Accordingly, in one aspect, the invention provides a method for determining the pH of a sample by contacting the sample with an indicator including a first fluorescent protein moiety whose emission intensity changes as the pH varies between 5 and 10, exciting the indicator, and the determining the intensity at a first wavelength. The emission intensity of the first fluorescent protein moiety indicates the pH of the sample.

In another aspect, the invention provides a method for determining the pH of a region of a cell by introducing into the cell a polynucleotide encoding a polypeptide including a first fluorescent protein moiety whose emission intensity changes as the pH varies between 5 and 10, culturing the cell under conditions that permit expression of the polynucleotide, and determining the intensity at a first wavelength. The emission intensity of the first fluorescent protein moiety indicates the pH of the sample.

In a further aspect, the invention provides a functional engineered fluorescent protein whose amino acid sequence is substantially identical to the amino acid sequence of the 238 amino acid Aequorea victoria green fluorescence protein shown in FIG. 3 of U.S. Ser. No. 08/911,825 (SEQ ID NO: 2), and whose emission intensity changes as pH varies between 5 and 10.

In another aspect, the invention provides a polynucleotide encoding the functional engineered fluorescent protein.

The invention also includes a kit useful for the detection of pH in a sample, e.g., a region of a cell. The kit includes a carrier means containing one or more containers comprising a first container containing a polynucleotide encoding a polypeptide including a first fluorescent protein moiety whose emission intensity changes as the pH varies between 5 and 10.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic diagram depicting fluorescent protein sensors used as indicators of intracellular pH.

FIGS. 2A and 2B are graphs showing absorbance as a function of wavelength for the fluorescent protein pH sensor EYFP (SEQ ID NO: 6) at various wavelengths (FIG. 2A), and the pH dependency of fluorescence of various GFP fluorescent protein sensors in vitro and in cells (FIG. 2B). The fluorescence intensity of purified recombinant GFP mutant protein (solid symbols) as a function of pH was measured in a microplate fluorometer. The fluorescence of the Golgi region of HeLa cells expressing proteins having the 81 N-terminal amino acids of the type II membrane-anchored protein galactosyltransferase (GT:UDP-galactose-β,1,4-galactosyltransferase. EC 2.4.1.22) ("GT") fused to EYFP, or EGFP, i.e., GT-EYFP or ET-EGFP (open symbols) was determined during pH titration with the ionophores monensin/nigericin in high KCL solutions.

FIGS. 3A and 3B are graphs showing ratiometric measurements of pH_(G) by cotransfecting HeLa cells with polynucleotides encoding GT-ECFP and GT-EYFP. FIG. 3A is a graph showing single-wave fluorescence intensities of GT-EYFP and GT-ECFP in the Golgi region of a HeLa cell. FIG. 3B is a graph showing the ratio of GT-EYFP/GT-ECFP fluorescence in the same cell as a function of time.

DETAILED DESCRIPTION

The invention provides genes encoding fluorescent sensor proteins, or fragments thereof, whose fluorescence is sensitive to changes in pH at a range between 5 and 10. The proteins of the invention are useful for measuring the pH of a sample. The sample can be a biological sample and can include an intracellular region of a cell, such as the lumen of the mitochondria or golgi. The pH of a sample is determined by observing the fluorescence of the fluorescent sensor protein.

The fluorescent protein pH sensor have a broad applicability to cells and organisms that are amenable to gene transfer. Problems associated with the use of other agents used to measure pH, e.g., problems associated with permeabilizing cells to ester-containing agents, leakage of agents, or hydrolysis of agents are avoided. With the fluorescent protein pH sensors of the invention, no leakage occurs over the course of a typical measurement, even when the measurement is made at 37° C.

Compositions and methods described herein also avoid the need to express and purify large quantities of soluble recombinant protein, purify and label it in vitro, microinject it back into cells. An important advantage of the fluorescent protein pH sensors of the invention is they can be delivered to cells in the form of polynucleotides encoding the protein sensor fused to a targeting signal or signals. The targeting signal directs the expression of the protein sensors to restricted cell locations. Thus, it is possible to measure the pH of a precisely defined cellular region or organelle.

Polynucleotides and Polypeptides

In a first aspect, the invention provides a functional engineered fluorescent protein whose amino acid sequence is substantially identical to the 238 amino acid Aequorea victoria green fluorescence protein shown in FIG. 3 of U.S. Ser. No. 08/911,825 (SEQ ID NO: 2). The term "fluorescent protein" refers to any protein capable of emitting light when excited with appropriate electromagnetic radiation, and which has an amino acid sequence that is either natural or engineered and is derived from the amino acid sequence of Aequorea-related fluorescent protein. The term "fluorescent protein pH sensor" refers to a fluorescent protein whose emitted light varies with changes in pH from 5 to 10.

The invention also includes functional polypeptide fragments of a fluorescent protein pH sensor. As used herein, the term "functional polypeptide fragment" refers to a polypeptide which possesses biological function or activity which is identified through a defined functional assay and which is associated with a particular biologic, morphologic, or phenotypic alteration in the cell. The term "functional fragments of a functional engineered fluorescent protein" refers to fragments of a functional engineered protein that retain a function of the engineered fluorescent protein, e.g., the ability to fluoresce in a pH-dependent manner over the pH range 5 to 10. Biologically functional fragments can vary in size from a polypeptide fragment as small as an epitope to a large polypeptide.

Minor modifications of the functional engineered fluorescent protein may result in proteins which have substantially equivalent activity as compared to the unmodified counterpart polypeptide as described herein. Such modifications may be deliberate, as by site-directed mutagenesis, or may be spontaneous. All of the polypeptides produced by these modifications are included herein as long as the pH-dependent fluorescence of the engineered protein still exists.

A functional engineered fluorescent protein includes amino acid sequences substantially the same as the sequence set forth in SEQ ID NO: 2, and whose emission intensity changes as pH varies between 5 and 10. In some embodiments the emission intensity of the functional engineered fluorescent protein changes as pH varies between 5 and 8.5.

By "substantially identical" is meant a protein or polypeptide that retains the activity of a functional engineered protein, or nucleic acid encoding the same, and which exhibits at least 80%, preferably 85%, more preferably 90%, and most preferably 95% homology to a reference amino acid or nucleic acid sequence. For polypeptides, the length of comparison sequences will generally be at least 16 amino acids, preferably at least 20 amino acids, more preferably at least 25 amino acids, and most preferably 35 amino acids. For nucleic acids, the length of comparison sequences will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 110 nucleotides.

By "substantially identical" is meant an amino acid sequence which differs only by conservative amino acid substitutions, for example, substitution of one amino acid for another of the same class (e.g., valine for glycine, arginine for lysine, etc.) or by one or more non-conservative substitutions, deletions, or insertions located at positions of the amino acid sequence which do not destroy the function of the protein (assayed, e.g., as described herein). Preferably, such a sequence is at least 85%, more preferably 90%, more preferably 95%, more preferably 98%, and most preferably 99% identical at the amino acid level to one of the sequences of EGFP (SEQ ID NO: 4), EYFP (SEQ ID NO: 6), ECFP (SEQ ID NO: 8), or EYFP-V68L/Q69K (SEQ ID NO: 10).

Homology is typically measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705). Such software matches similar sequences by assigning degrees of homology to various insertions, deletions, substitutions, and other modifications. Conservative substitutions typically include substitutions within the following groups: glycine alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

In some embodiments, the amino acid sequence of the protein includes one of the following sets of substitutions in the amino acid sequence of the Aequorea green fluorescent protein (SEQ ID NO: 2): F64L/S65T/H231L, referred to herein as EGFP (SEQ ID NO: 4); S65G/S72A/T203Y/H231L, referred to herein as EYFP (SEQ ID NO: 6); S65G/V68L/Q69K/S72A/T203Y/H231L, referred to herein as EYFP-V68L/Q69K (SEQ ID NO: 10); or K26R/F64L/S65T/Y66W/N146I/M153T/V163A/N164H/H231L, referred to herein as ECFP (SEQ ID NO: 8). The DNA sequences and corresponding amino acid sequences of EGFP, EYFP, ECFP, and EYFP-V68L/Q69K are shown in Tables 1-8, respectively. The amino acids are numbered with the amino acid following the iniating methionine assigned the `1` position. Thus, F64L corresponds to a substitution of leucine for phenylalanine in the 64th amino acid following the iniating methionine.

                                      TABLE 1                                      __________________________________________________________________________     EGFP Nucleic Acid Sequence (SEQ ID NO:3)                                       __________________________________________________________________________     ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGAC                     GGCGACGTAAACGGCCACAGGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTAC                   GGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACC                   CTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAG                   CAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC                   TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTG                   GTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCAC                   AAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAAC                   GGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCC                   GACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC                   TACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTC                   CTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA                 __________________________________________________________________________

                                      TABLE 2                                      __________________________________________________________________________     EGFP Amino Acid Sequence (SEQ ID NO:4)                                         __________________________________________________________________________     MVSKGEELFTGVVPILVELDGDVNGHRFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPT                     LVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTL                   VNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLA                   DHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK*                 __________________________________________________________________________

                                      TABLE 3                                      __________________________________________________________________________     EYFP Nucleic Acid Sequence (SEQ ID NO:5)                                       __________________________________________________________________________     ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGAC                     GGCGACGTAAACGGCCACAGGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTAC                   GGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACC                   CTCGTGACCACCTTCGGCTACGGCGTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAG                   CAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC                   TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTG                   GTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCAC                   AAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAAC                   GGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCC                   GACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC                   TACCTGAGCTACCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTC                   CTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA                 __________________________________________________________________________

                                      TABLE 4                                      __________________________________________________________________________     EYFP Amino Acid Sequence (SEQ ID NO:6)                                         __________________________________________________________________________     MVSKGEELFTGVVPILVELDGDVNGHRFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPT                     LVTTFGYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTL                   VNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLA                   DHYQQNTPIGDGPVLLPDNHYLSYQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK*                 __________________________________________________________________________

                                      TABLE 5                                      __________________________________________________________________________     ECFP Nucleic Acid Sequence (SEQ ID NO:7)                                       __________________________________________________________________________     ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGAC                     GGCGACGTAAACGGCCACAGGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTAC                   GGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACC                   CTCGTGACCACCCTGACCTGGGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAG                   CAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC                   TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTG                   GTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCAC                   AAGCTGGAGTACAACTACATCAGCCACAACGTCTATATCACCGCCGACAAGCAGAAGAAC                   GGCATCAAGGCCCACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCC                   GACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC                   TACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTC                   CTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA                 __________________________________________________________________________

                                      TABLE 6                                      __________________________________________________________________________     ECFP Amino Acid Sequence (SEQ ID NO:8)                                         __________________________________________________________________________     MVSKGEELFTGVVPILVELDGDVNGHRFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPT                     LVTTLTWGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTL                   VNRIELKGIDFKEDGNILGHKLEYNYISHNVYITADKQKNGIKAHFKIRHNIEDGSVQLA                   DHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK*                 __________________________________________________________________________

                                      TABLE 7                                      __________________________________________________________________________     EYFP-V68L/Q69K Nucleic Acid Sequence (SEQ ID NO:9)                             __________________________________________________________________________     ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGAC                     GGCGACGTAAACGGCCACAGGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTAC                   GGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACC                   CTCGTGACCACCTTCGGCTACGGCCTGAAGTGCTTCGCCCGCTACCCCGACCACATGAAG                   CAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC                   TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTG                   GTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCAC                   AAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAAC                   GGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCC                   GACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC                   TACCTGAGCTACCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTC                   CTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA                 __________________________________________________________________________

                                      TABLE 8                                      __________________________________________________________________________     EYFP-V68L/Q69K Amino Acid Sequence                                             __________________________________________________________________________     MVSKGEELFTGVVPILVELDGDVNGHRFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPT                     LVTTFGYGLKCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTL                   VNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLA                   DHYQQNTPIGDGPVLLPDNHYLSYQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK*                 __________________________________________________________________________

In some embodiments, the protein or polypeptide is substantially purified. By "substantially pure protein or polypeptide" is meant an functional engineered fluorescent polypeptide which has been separated from components which naturally accompany it. Typically, the protein or polypeptide is substantially pure when it is at least 60%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, of the protein. A substantially pure protein may be obtained, for example, by extraction from a natural source (e.g., a plant cell); by expression of a recombinant nucleic acid encoding a functional engineered fluorescent protein; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, e.g., those described in column chromatography, polyacrylamide gel electrophoresis, or by HPLC analysis.

A protein or polypeptide is substantially free of naturally associated components when it is separated from those contaminants which accompany it in its natural state. Thus, a protein or polypeptide which is chemically synthesized or produced in a cellular system different from the cell from which it naturally originates will be substantially free from its naturally associated components. Accordingly, substantially pure polypeptides include those derived from eukaryotic organisms but synthesized in E. coli or other prokaryotes.

The invention also provides polynucleotides encoding the functional engineered fluorescent protein described herein. These polynucleotides include DNA, cDNA, and RNA sequences which encode functional engineered fluorescent proteins. It is understood that all polynucleotides encoding functional engineered fluorescent proteins are also included herein, as long as they encode a protein or polypeptide whose fluorescent emission intensity changes as pH varies between 5 and 10. Such polynucleotides include naturally occurring, synthetic, and intentionally manipulated polynucleotides. For example, the polynucleotide may be subjected to site-directed mutagenesis. The polynucleotides of the invention include sequences that are degenerate as a result of the genetic code. Therefore, all degenerate nucleotide sequences are included in the invention as long as the amino acid sequence of the functional engineered fluorescent protein or derivative is functionally unchanged.

Specifically disclosed herein is a polynucleotide sequence encoding a functional engineered fluorescent protein that includes one of the following sets of substitutions in the amino acid sequence of the Aequorea green fluorescent protein (SEQ ID NO: 2): S65G/S72A/T203Y/H231L, S65G/V68L/Q69K/S72A/T203Y/H₂₃₁ L, or K26R/F64L/S65T/Y66W/N146I/M153T/V163A/N164H/H231L.

The term "polynucleotide" refers to a polymeric form of nucleotides of at least 10 bases in length. The nucleotides can be ribonucleotides, deoxynucleotides, or modified forms of either type of nucleotide. The term includes single and double stranded forms of DNA. By "isolated polynucleotide" is meant a polynucleotide that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector, e.g., an expression vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA) independent of other sequences.

A "substantially identical" nucleic acid sequence codes for a substantially identical amino acid sequence as defined above.

The functional engineered fluorescent protein can also include a targeting sequence to direct the fluorescent protein to particular cellular sites by fusion to appropriate organellar targeting signals or localized host proteins. A polynucleotide encoding a targeting sequence can be ligated to the 5' terminus of a polynucleotide encoding the fluorescence such that the targeting peptide is located at the amino terminal end of the resulting fusion polynucleotide/polypeptide. The targeting sequence can be, e.g., a signal peptide. In the case of eukaryotes, the signal peptide is believed to function to transport the fusion polypeptide across the endoplasmic reticulum. The secretory protein is then transported through the Golgi apparatus, into secretory vesicles and into the extracellular space or, preferably, the external environment. Signal peptides which can be utilized according to the invention include pre-pro peptides which contain a proteolytic enzyme recognition site. Other signal peptides with similar properties to pro-calcitonin described herein are known to those skilled in the art, or can be readily ascertained without undue experimentation.

The targeting sequence can also be a nuclear localization sequence, an endoplasmic reticulum localization sequence, a peroxisome localization sequence, a mitochondrial localization sequence, or a localized protein. Targeting sequences can be targeting sequences which are described, for example, in "Protein Targeting", chapter 35 of Stryer, L., Biochemistry (4th ed.). W.H. Freeman, 1995. The localization sequence can also be a localized protein. Some important targeting sequences include those targeting the nucleus (KKKRK, SEQ ID NO: 15), mitochondrion (the 12 amino terminal acids of the cytochrome c oxidase subunit IV gene, or the amino terminal sequence MLRTSSLFTRRVQPSLFRNILRLQST-, SEQ ID NO: 16), endoplasmic reticulum (KDEL (SEQ ID NO: 17) at C-terminus, assuming a signal sequence present at N-terminus), peroxisome (SKF at C-terminus), prenylation or insertion into plasma membrane (CaaX, CC, CXC, or CCXX at C-terminus), cytoplasmic side of plasma membrane (fusion to SNAP-25), or the Golgi apparatus (fusion to the amino terminal 81 amino acids of human type II membrane-anchored protein galactosyltransferase, or fusion to furin).

Examples of targeting sequences linked to functional engineered fluorescent proteins include GT-EYFP, GT-ECFP, GT-EGFP, and GT-EYFP-V68L/Q69K, which are targeted to the Golgi apparatus using sequences from the GT protein; and EYFP-mito (SEQ ID NO: 14) and EGFP-mito (SEQ ID NO: 12), which are targeted to the mitochondrial matrix using sequences from the amino terminal region of the cytochrome c oxidase subunit IV gene. The EYFP, ECFP, EGFP, and EYFP-V68L/Q69K amino acid sequences and corresponding polynucleotide sequences are described above. The GT-derived targeting sequence corresponds to the 81 amino terminal amino acids of the human GT sequence. The GT amino acid sequences, and the polynucleotide sequences encoding the GT amino acid sequences, are described in Genbank Accession No. M70427 and Mengle-Gaw et al., Biochem. Biophys. Res. Commun. 176 (3), 1269-1276 (1991).

Polynucleotide sequences encoding EYFP-mito and ECFP-mito, along with their encoded amino acid sequences, are shown in Tables 9-12.

                                      TABLE 9                                      __________________________________________________________________________     ECFP-mito Nucleic Acid Sequence (SEQ ID NO:11)                                 __________________________________________________________________________     ATGCTGAGCCTGCGCCAGAGCATCCGCTTCTTCAAGCGCAGCGGCATCATGGTGAGCAAG                     GGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAAC                   GGCCACAGGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACC                   CTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACC                   CTGACCTGGGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTC                   TTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGAC                   GGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATC                   GAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTAC                   AACTACATCAGCCACAACGTCTATATCACCGCCGACAAGCAGAAGAACGGCATCAAGGCC                   CACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAG                   CAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACC                   CAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTC                   GTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA                             __________________________________________________________________________

                                      TABLE 10                                     __________________________________________________________________________     ECFP-mito Amino Acid Sequence (SEQ ID NO:12)                                   __________________________________________________________________________     MLSLRQSIRFFKRSGIMVSKGEELFTGVVPILVELDGDVNGHRFSVSGEGEGDATYGKLT                     LKFICTTGKLPVPWPTLVTTLTWGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDD                   GNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYISHNVYITADKQKNGIKA                   HFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEF                   VTAAGITLGMDELYK*                                                             __________________________________________________________________________

                                      TABLE 11                                     __________________________________________________________________________     EYFP-mito Nucleic Acid Sequence (SEQ ID NO:13)                                 __________________________________________________________________________     ATGCTGAGCCTGCGCCAGAGCATCCGCTTCTTCAAGCGCAGCGGCATCATGGTGAGCAAG                     GGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAAC                   GGCCACAGGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACC                   CTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACC                   TTCGGCTACGGCGTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTC                   TTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGAC                   GGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATC                   GAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTAC                   AACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTG                   AACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAG                   CAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCTAC                   CAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTC                   GTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA                             __________________________________________________________________________

                                      TABLE 12                                     __________________________________________________________________________     EYFP-mito Amino Acid Sequence (SEQ ID NO:14)                                   __________________________________________________________________________     MLSLRQSIRFFKRSGIMVSKGEELFTGVVPILVELDGDVNGHRFSVSGEGEGDATYGKLT                     LKFICTTGKLPVPWPTLVTTFGYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDD                   GNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKV                   NFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSYQSALSKDPNEKRDHMVLLEF                   VTAAGITLGMDELYK*                                                             __________________________________________________________________________

The fluorescent indicators can be produced as proteins fused to other fluorescent indicators or targeting sequences by recombinant DNA technology. Recombinant production of fluorescent proteins involves expressing nucleic acids having sequences that encode the proteins. Nucleic acids encoding fluorescent proteins can be obtained by methods known in the art. For example, a nucleic acid encoding the protein can be isolated by polymerase chain reaction of cDNA from A. victoria using primers based on the DNA sequence of A. victoria green fluorescent protein. PCR methods are described in, for example, U.S. Pat. No. 4,683,195; Mullis, et al. Cold Spring Harbor Symp. Quant. Biol. 51:263 (1987), and Erlich, ed., PCR Technology, (Stockton Press, NY, 1989). Mutant versions of fluorescent proteins can be made by site-specific mutagenesis of other acids encoding fluorescent proteins, or by random mutagenesis caused by increasing the error rate of PCR of the original polynucleotide with 0.1 mM MnCl₂ and unbalanced nucleotide concentrations. See, e.g., U.S. patent application Ser. No. 08/337,915, filed Nov. 10, 1994 or International application PCT/US95/14692, filed Nov. 10, 1995.

The construction of expression vectors and the expression of genes in transfected cells involves the use of molecular cloning techniques also well known in the art. Sambrook et al., Molecular Cloning--A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., (1989) and Current Protocols in Molecular Biology, F. M. Ausubel et al., eds., (Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., most recent Supplement).

Nucleic acids used to transfect cells with sequences coding for expression of the polypeptide of interest generally will be in the form of an expression vector including expression control sequences operatively linked to a nucleotide sequence coding for expression of the polypeptide. As used herein, "operatively linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A control sequence operatively linked to a coding sequence is ligated such that expression of the coding sequence is achieved under conditions compatible with the control sequences. "Control sequence" refers to polynucleotide sequences which are necessary to effect the expression of coding and non-coding sequences to which they are ligated. Control sequences generally include promoter, ribosomal binding site, and transcription termination sequence. The term "control sequences" is intended to include, at a minimum, components whose presence can influence expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.

As used herein, the term "nucleotide sequence coding for expression of" a polypeptide refers to a sequence that, upon transcription and translation of mRNA, produces the polypeptide. This can include sequences containing, e.g., introns. As used herein, the term "expression control sequences" refers to nucleic acid sequences that regulate the expression of a nucleic acid sequence to which it is operatively linked. Expression control sequences are operatively linked to a nucleic acid sequence when the expression control sequences control and regulate the transcription and, as appropriate, translation of the nucleic acid sequence. Thus, expression control sequences can include appropriate promoters, enhancers, transcription terminators, a start codon (i.e., ATG) in front of a protein-encoding gene, splicing signals for introns, maintenance of the correct reading frame of that gene to permit proper translation of the mRNA, and stop codons.

Methods which are well known to those skilled in the art can be used to construct expression vectors containing the fluorescent indicator coding sequence and appropriate transcriptional/translational control signals. These methods include in vitro recombinant DNA techniques, synthetic techniques and in vivo recombination/genetic recombination. (See, for example, the techniques described in Maniatis, et al., Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y., 1989). Transformation of a host cell with recombinant DNA may be carried out by conventional techniques as are well known to those skilled in the art. Where the host is prokaryotic, such as E. coli, competent cells which are capable of DNA uptake can be prepared from cells harvested after exponential growth phase and subsequently treated by the CaCl₂ method by procedures well known in the art. Alternatively, MgCl₂ or RbCl can be used. Transformation can also be performed after forming a protoplast of the host cell or by electroporation.

When the host is a eukaryote, such methods of transfection of DNA as calcium phosphate co-precipitates, conventional mechanical procedures such as microinjection, electroporation, insertion of a plasmid encased in liposomes, or virus vectors may be used. Eukaryotic cells can also be cotransfected with DNA sequences encoding the fusion polypeptide of the invention, and a second foreign DNA molecule encoding a selectable phenotype, such as the herpes simplex thymidine kinase gene. Another method is to use a eukaryotic viral vector, such as simian virus 40 (SV40) or bovine papilloma virus, to transiently infect or transform eukaryotic cells and express the protein. (Eukaryotic Viral Vectors, Cold Spring Harbor Laboratory, Gluzman ed., 1982).

Techniques for the isolation and purification of polypeptides of the invention expressed in prokaryotes or eukaryotes may be by any conventional means such as, for example, preparative chromatographic separations and immunological separations such as those involving the use of monoclonal or polyclonal antibodies or antigen.

A variety of host-expression vector systems may be utilized to express fluorescent indicator coding sequence. These include but are not limited to microorganisms such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing a fluorescent indicator coding sequence; yeast transformed with recombinant yeast expression vectors containing the fluorescent indicator coding sequence; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing a fluorescent indicator coding sequence; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing a fluorescent indicator coding sequence; or animal cell systems infected with recombinant virus expression vectors (e.g., retroviruses, adenovirus, vaccinia virus) containing a fluorescent indicator coding sequence, or transformed animal cell systems engineered for stable expression.

Depending on the host/vector system utilized, any of a number of suitable transcription and translation elements, including constitutive and inducible promoters, transcription enhancer elements, transcription terminators, etc. may be used in the expression vector (see, e.g., Bitter, et al., Methods in Enzymology 153:516-544, 1987). For example, when cloning in bacterial systems, inducible promoters such as pL of bacteriophage λ, plac, ptrp, ptac (ptrp-lac hybrid promoter) and the like may be used. When cloning in mammalian cell systems, promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the retrovirus long terminal repeat; the adenovirus late promoter; the vaccinia virus 7.5 K promoter) may be used. Promoters produced by recombinant DNA or synthetic techniques may also be used to provide for transcription of the inserted fluorescent indicator coding sequence.

In bacterial systems a number of expression vectors may be advantageously selected depending upon the use intended for the fluorescent indicator expressed. For example, when large quantities of the fluorescent indicator are to be produced, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Those which are engineered to contain a cleavage site to aid in recovering fluorescent indicator are preferred. In yeast, a number of vectors containing constitutive or inducible promoters may be used. For a review see, Current Protocols in Molecular Biology, Vol. 2, Ed. Ausubel, et al., Greene Publish. Assoc. & Wiley Interscience, Ch. 13, 1988; Grant, et al., Expression and Secretion Vectors for Yeast, in Methods in Enzymology, Eds. Wu & Grossman, 31987, Acad. Press, N.Y., Vol. 153, pp.516-544, 1987; Glover, DNA Cloning, Vol. II, IRL Press, Wash., D.C., Ch. 3, 1986; and Bitter, Heterologous Gene Expression in Yeast, Methods in Enzymology, Eds. Berger & Kimmel, Acad. Press, N.Y., Vol. 152, pp. 673-684, 1987; and The Molecular Biology of the Yeast Saccharomyces, Eds. Strathern et al., Cold Spring Harbor Press, Vols. I and II, 1982. A constitutive yeast promoter such as ADH or LEU2 or an inducible promoter such as GAL may be used (Cloning in Yeast, Ch. 3, R. Rothstein In: DNA Cloning Vol.11, A Practical Approach, Ed. D M Glover, IRL Press, Wash., D.C., 1986). Alternatively, vectors may be used which promote integration of foreign DNA sequences into the yeast chromosome.

In cases where plant expression vectors are used, the expression of a fluorescent indicator coding sequence may be driven by any of a number of promoters. For example, viral promoters such as the 35S RNA and 19S RNA promoters of CaMV (Brisson, et al., Nature 310:511-514, 1984), or the coat protein promoter to TMV (Takamatsu, et al., EMBO J. 6:307-311, 1987) may be used; alternatively, plant promoters such as the small subunit of RUBISCO (Coruzzi, et al., 1984, EMBO J. 3:1671-1680; Broglie, et al., Science 224:838-843, 1984); or heat shock promoters, e.g., soybean hsp17.5-E or hsp17.3-B (Gurley, et al., Mol. Cell. Biol. 6:559-565, 1986) may be used. These constructs can be introduced into plant cells using Ti plasmids, Ri plasmids, plant virus vectors, direct DNA transformation, microinjection, electroporation, etc. For reviews of such techniques see, for example, Weissbach & Weissbach, Methods for Plant Molecular Biology, Academic Press, NY, Section VIII, pp. 421-463, 1988; and Grierson & Corey, Plant Molecular Biology, 2d Ed., Blackie, London, Ch. 7-9, 1988.

An alternative expression system which could be used to express fluorescent indicator is an insect system. In one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in Spodoptera frugiperda cells. The fluorescent indicator coding sequence may be cloned into non-essential regions (for example, the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of the fluorescent indicator coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect Spodoptera frugiperda cells in which the inserted gene is expressed, see Smith, et al., J. Viol. 46:584, 1983; Smith, U.S. Pat. No. 4,215,051.

Eukaryotic systems, and preferably mammalian expression systems, allow for proper post-translational modifications of expressed mammalian proteins to occur. Eukaryotic cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, phosphorylation, and, advantageously secretion of the gene product should be used as host cells for the expression of fluorescent indicator. Such host cell lines may include but are not limited to CHO, VERO, BHK, HeLa, COS, MDCK, Jurkat, HEK-293, and WI38. Primary cell lines, such as neonatal rat myocytes, can also be used.

Mammalian cell systems which utilize recombinant viruses or viral elements to direct expression may be engineered. For example, when using adenovirus expression vectors, the fluorescent indicator coding sequence may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the fluorescent indicator in infected hosts (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA, 81: 3655-3659, 1984). Alternatively, the vaccinia virus 7.5K promoter may be used (e.g., see, Mackett, et al., Proc. Natl. Acad. Sci. USA,79: 7415-7419, 1982; Mackett, et al., J. Virol. 49: 857-864, 1984; Panicali, et al., Proc. Natl. Acad. Sci. USA 79: 4927-4931, 1982). Of particular interest are vectors based on bovine papilloma virus which have the ability to replicate as extrachromosomal elements (Sarver, et al., Mol. Cell. Biol. 1:486, 1981). Shortly after entry of this DNA into mouse cells, the plasmid replicates to about 100 to 200 copies per cell. Transcription of the inserted cDNA does not require integration of the plasmid into the host's chromosome, thereby yielding a high level of expression. These vectors can be used for stable expression by including a selectable marker in the plasmid, such as the neo gene. Alternatively, the retroviral genome can be modified for use as a vector capable of introducing and directing the expression of the fluorescent indicator gene in host cells (Cone & Mulligan, Proc. Natl. Acad. Sci. USA, 81:6349-6353, 1984). High level expression may also be achieved using inducible promoters, including, but not limited to, the metallothionein IIA promoter and heat shock promoters.

The recombinant nucleic acid can be incorporated into an expression vector including expression control sequences operatively linked to the recombinant nucleic acid. The expression vector can be adapted for function in prokaryotes or eukaryotes by inclusion of appropriate promoters, replication sequences, markers, etc.

DNA sequences encoding the fluorescence indicator polypeptide of the invention can be expressed in vitro or in vivo by DNA transfer into a suitable recombinant host cell. As used herein, "recombinant host cells" are cells in which a vector can be propagated and its DNA expressed. The term also includes any progeny of the subject host cell. It is understood that all progeny may not be identical to the parental cell since there may be mutations that occur during replication. However, such progeny are included when the term "recombinant host cell" is used. Methods of stable transfer, in other words when the foreign DNA is continuously maintained in the host, are known in the art.

The expression vector can be transfected into a host cell for expression of the recombinant nucleic acid. Recombinant host cells can be selected for high levels of expression in order to purify the fluorescent indicator fusion protein. E. coli is useful for this purpose. Alternatively, the host cell can be a prokaryotic or eukaryotic cell selected to study the activity of an enzyme produced by the cell. In this case, the linker peptide is selected to include an amino acid sequence recognized by the protease. The cell can be, e.g., a cultured cell or a cell taken in vivo from a transgenic animal.

Transgenic Animals

In another embodiment, the invention provides a transgenic non-human animal that expresses a polynucleotide sequence which encodes a fluorescent protein pH sensor.

The "non-human animals" of the invention comprise any non-human animal having a polynucleotide sequence which encodes a fluorescent indicator. Such non-human animals include vertebrates such as rodents, non-human primates, sheep, dog, cow, pig, amphibians, and reptiles. Preferred non-human animals are selected from the rodent family including rat and mouse, most preferably mouse. The "transgenic non-human animals" of the invention are produced by introducing "transgenes" into the germline of the non-human animal. Embryonal target cells at various developmental stages can be used to introduce transgenes. Different methods are used depending on the stage of development of the embryonal target cell. The zygote is the best target for micro-injection. In the mouse, the male pronucleus reaches the size of approximately 20 micrometers in diameter which allows reproducible injection of 1-2 pl of DNA solution. The use of zygotes as a target for gene transfer has a major advantage in that in most cases the injected DNA will be incorporated into the host gene before the first cleavage (Brinster et al., Proc. Natl. Acad. Sci. USA 82:4438-4442, 1985). As a consequence, all cells of the transgenic non-human animal will carry the incorporated transgene. This will in general also be reflected in the efficient transmission of the transgene to offspring of the founder since 50% of the germ cells will harbor the transgene. Microinjection of zygotes is the preferred method for incorporating transgenes in practicing the invention.

The term "transgenic" is used to describe an animal which includes exogenous genetic material within all of its cells. A "transgenic" animal can be produced by cross-breeding two chimeric animals which include exogenous genetic material within cells used in reproduction. Twenty-five percent of the resulting offspring will be transgenic, i.e., animals which include the exogenous genetic material within all of their cells in both alleles. 50% of the resulting animals will include the exogenous genetic material within one allele and 25% will include no exogenous genetic material.

Retroviral infection can also be used to introduce transgene into a non-human animal. The developing non-human embryo can be cultured in vitro to the blastocyst stage. During this time, the blastomeres can be targets for retro viral infection (Jaenisch, R., Proc. Natl. Acad. Sci USA 73:1260-1264, 1976). Efficient infection of the blastomeres is obtained by enzymatic treatment to remove the zona pellucida (Hogan, et al. (1986) in Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). The viral vector system used to introduce the transgene is typically a replication-defective retrovirus carrying the transgene (Jahner, et al., Proc. Natl. Acad. Sci. USA 82:6927-6931, 1985; Van der Putten, et al., Proc. Natl. Acad. Sci USA 82:6148-6152, 1985). Transfection is easily and efficiently obtained by culturing the blastomeres on a monolayer of virus-producing cells (Van der Putten, supra; Stewart, et al., EMBO J. 6:383-388, 1987). Alternatively, infection can be performed at a later stage. Virus or virus-producing cells can be injected into the blastocoele (D. Jahner et al., Nature 298:623-628, 1982). Most of the founders will be mosaic for the transgene since incorporation occurs only in a subset of the cells which formed the transgenic nonhuman animal. Further, the founder may contain various retro viral insertions of the transgene at different positions in the genome which generally will segregate in the offspring. In addition, it is also possible to introduce transgenes into the germ line, albeit with low efficiency, by intrauterine retro viral infection of the midgestation embryo (D. Jahner et al., supra). A third type of target cell for transgene introduction is the embryonal stem cell (ES). ES cells are obtained from pre-implantation embryos cultured in vitro and fused with embryos (M. J. Evans et al. Nature 292:154-156, 1981; M. O. Bradley et al., Nature 309: 255-258,1984; Gossler, et al., Proc. Natl. Acad. Sci USA 83: 9065-9069, 1986; and Robertson et al., Nature 322:445-448, 1986). Transgenes can be efficiently introduced into the ES cells by DNA transfection or by retrovirus-mediated transduction. Such transformed ES cells can thereafter be combined with blastocysts from a nonhuman animal. The ES cells thereafter colonize the embryo and contribute to the germ line of the resulting chimeric animal. (For review see Jaenisch, R., Science 240: 1468-1474, 1988).

"Transformed" means a cell into which (or into an ancestor of which) has been introduced, by means of recombinant nucleic acid techniques, a heterologous polynucleotide. "Heterologous" refers to a polynucleotide sequence that either originates from another species or is modified from either its original form or the form primarily expressed in the cell.

"Transgene" means any piece of DNA which is inserted by artifice into a cell, and becomes part of the genome of the organism (i.e., either stably integrated or as a stable extrachromosomal element) which develops from that cell. Such a transgene may include a gene which is partly or entirely heterologous (i.e., foreign) to the transgenic organism, or may represent a gene homologous to an endogenous gene of the organism. Included within this definition is a transgene created by the providing of an RNA sequence which is transcribed into DNA and then incorporated into the genome. The transgenes of the invention include DNA sequences which encode which encodes the fluorescent indicator which may be expressed in a transgenic non-human animal. The term "transgenic" as used herein additionally includes any organism whose genome has been altered by in vitro manipulation of the early embryo or fertilized egg or by any transgenic technology to induce a specific gene knockout. The term "gene knockout" as used herein, refers to the targeted disruption of a gene in vivo with complete loss of function that has been achieved by any transgenic technology familiar to those in the art. In one embodiment, transgenic animals having gene knockouts are those in which the target gene has been rendered nonfunctional by an insertion targeted to the gene to be rendered non-functional by homologous recombination. As used herein, the term "transgenic" includes any transgenic technology familiar to those in the art which can produce an organism carrying an introduced transgene or one in which an endogenous gene has been rendered non-functional or "knocked out."

Detection of pH Using Fluorescent Indicator Proteins

In another embodiment, the invention provides a method for determining the pH of a sample by contacting the sample with an indicator including a first fluorescent protein moiety whose emission intensity changes as pH varies between pH 5 and 10, exciting the indicator, and then determining the intensity of light emitted by the first fluorescent protein moiety at a first wavelength. The emission intensity of the first fluorescent protein moiety indicates the pH of the sample.

The fluorescent protein moiety can be a functional engineered protein substantially identical to the amino acid sequence of Aequorea green fluorescence protein (SEQ ID NO: 2). Preferred green fluorescence proteins include those having a functional engineered fluorescent protein that includes one of the following sets of substitutions in the amino acid sequence of the Aequorea green fluorescent protein (SEQ ID NO: 2): S65G/S72A/T203Y/H231L, S65G/V68L/Q69K/S72A/T203Y/H231L, or K26R/F64L/S65T/Y66W/N146I/M153T/V163A/N164H/H231L.

The sample in which pH is to be measured can be a biological sample, e.g., a biological tissue such as an extracellular matrix, blood or lymphatic tissue, or a cell. The method is particularly suitable for measuring pH in a specific region of the cell, e.g., the cytosol, or an organellar space such as the inner mitochondrial matrix, the lumen of the Golgi, cytosol, the endoplasmic reticulum, the chloroplast lumen, the lumen of lysosome, or the lumen of an endosome.

In some embodiments, the first fluorescent protein moiety is linked to a targeting sequence that directs the fluorescent protein to a desired cellular compartment. Examples of targeting sequences include the amino terminal 81 amino acids of human type II membrane-anchored protein galactosyltransferase for directing the fluorescent indicator protein to the Golgi and the amino terminal 12 amino acids of the presequence of subunit IV of cytochrome c oxidase for directing a fluorescent pH indicator protein to the mitochondrial matrix. The 12 amino acids of the presequence of subunit IV of cytochrome c oxidase may be linked to the pH fluorescent indicator protein through a linker sequence, e.g., Arg-Ser-Gly-Ile (SEQ ID NO: 18).

In another embodiment, the invention provides a method of determining the pH of a region of a cell by introducing into the cell a polynucleotide encoding a polypeptide including an indicator having a first fluorescent protein moiety whose emission intensity changes as pH varies between 5 and 10, culturing the cell under conditions that permit expression of the polynucleotide; exciting the indicator; and determining the intensity of the light emitted by the first protein moiety at a first wavelength. The emission intensity of the first fluorescent protein moiety indicates the pH of the region of the cell in which the indicator is present.

The polynucleotide can be introduced using methods described above. Thus, the method can be used to measure intracellular pH in cells cultured in vitro, e.g., HeLa cells, or alternatively in vivo, e.g., in cells of an animal carrying a transgene encoding a pH-dependent fluorescent indicator protein.

Fluorescence in the sample can be measured using a fluorometer. In general, excitation radiation, from an excitation source having a first wavelength, passes through excitation optics. The excitation optics cause the excitation radiation to excite the sample. In response, fluorescent proteins in the sample emit radiation which has a wavelength that is different from the excitation wavelength. Collection optics then collect the emission from the sample. The device can include a temperature controller to maintain the sample at a specific temperature while it is being scanned. If desired, a multi-axis translation stage can be used to move a microtiter plate holding a plurality of samples in order to position different wells to be exposed. The multi-axis translation stage, temperature controller, auto-focusing feature, and electronics associated with imaging and data collection can be managed by an appropriately programmed digital computer. The computer also can transform the data collected during the assay into another format for presentation.

Methods of performing assays on fluorescent materials are well known in the art and are described in, e.g., Lakowicz, J. R., Principles of Fluorescence Spectroscopy, New York: Plenum Press (1983); Herman, B., Resonance energy transfer microscopy, in: Fluorescence Microscopy of Living Cells in Culture, Part B, Methods in Cell Biology, vol. 30, ed. Taylor, D. L. & Wang, Y. -L., San Diego: Academic Press (1989), pp. 219-243; Turro, N.J., Modern Molecular Photochemistry, Menlo Park: Benjamin/Cummings Publishing Col, Inc. (1978), pp. 296-361.

The pH can be analyzed on cells in vivo, or from samples derived from cells transfected with polynucleotides or proteins expressing the pH indicator proteins. Because fluorescent pH indicator proteins can be expressed recombinantly inside a cell, the pH in an intracellular region, e.g., an organelle, or an extracellular region of an organism can be determined simply by determining changes in fluorescence.

Fluorescent protein pH sensors have may vary in their respective pK_(a), and the differences in pK_(a) can be used to select the most suitable fluorescent protein sensor most suitable for a particular application. In general, a sensor protein should be used whose pK_(a) is close to the pH of the sample to be measured. Preferably the pK_(a) is within 1.5 pH unit of the sample. More preferably the pK_(a) is within 1 pH unit, and still more preferably the pK_(a) is within 0.5 pH unit of the sample.

Thus, a fluorescent protein pH sensor having a pK_(a) of about 7.1, e.g., the EYFP mutant described below, is preferred for determining the pH of cytosolic, Golgi, and mitochondrial matrix pH areas of a cell. For more acidic organelles, a fluorescence sensor protein having a lower pK_(a), e.g., a pK_(a) of about 6.1, is preferred.

To minimize artefactually low fluorescence measurements that occur due to cell movement or focusing, the fluorescence of a the fluorescent protein pH sensor can be compared to the fluorescence of a second sensor, e.g., a second fluorescent protein pH sensor, that is also present in the measured sample. The second fluorescent protein pH sensor should have an emission spectra distinct from the first fluorescent protein pH sensor so that the emission spectra of the two sensors can be distinguished. Because experimental conditions such as focusing and cell movement will affect fluorescence of the second sensor as well as the first sensor, comparing the relative fluorescence of the two sensors allows for the normalization of fluorescence.

A convenient method of comparing the samples is to compute the ratio of the fluorescence of the first fluorescent protein pH sensor to that of the second fluorescent protein pH sensor.

Kits

The materials and components described for use in the methods of the invention are ideally suited for the preparation of a kit. Such a kit may comprise a carrier means being compartmentalized to receive one or more container means such as vials, tubes, and the like, each of the container means comprising one of the separate elements to be used in the method. For example, one of the container means may comprise a polynucleotide encoding a fluorescent protein pH sensor. A second container may further comprise fluorescent protein pH sensor. The constituents may be present in liquid or lyophilized form, as desired.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to limit the scope of the invention described in the claims.

EXAMPLES Example 1 Construction of Fluorescent Protein pH Sensors

Fluorescent protein pH sensors were constructed by engineering site-specific mutations in polynucleotides encoding forms of the Aequorea victoria green fluorescent protein (GFP). The starting GFP variant was the polynucleotide encoding the GFP variant EGFP (for enhanced green fluorescent protein). The EGFP variant had the amino acid substitutions F64L/S65T/H231L relative to the wild-type Aequorea victoria GFP sequence.

The ECFP (enhanced cyan fluorescent protein) mutant was constructed by altering the EGFP polynucleotide sequence so that it encoded a protein having the amino acid substitutions K26R/F64L/S65T/Y66W/N146I/M153T/V163A/N164H/H231L relative to the wild-type GFP amino acid sequence. A second variant, named EYFP (enhanced yellow fluorescent protein) was constructed by altering the EGFP polynucleotide to encode a protein having the amino acid substitutions S65G/S72A/T203Y/H231L relative to the amino acid sequence of GFP. A third variant, named EYFP-V68L/Q69K, was constructed by altering the EGFP polynucleotide to encode a protein having the amino acid substitutions S65G/V68L/Q69K/S72A/T203Y/H231L relative to the amino acid sequence of GFP.

A HindIII site and Kozak consensus sequence (GCCACCATG) was introduced at the 5' end of the polynucleotide encoding the GFP variants, and an EcoR1 site was added at the 3' end of the gene of each indicator, and the fragments were ultimately ligated into the HindIII/EcoR1 sites of the mammalian expression vector pcDNA3 (Invitrogen). EGFP and EYFP mutant proteins with no targeting signals were used as indicators of pH in the cytosol or nucleus indicators.

To construct fluorescent protein pH sensors to use as pH indicators in the Golgi, polynucleotides encoding the 81 N-terminal amino acids of the type II membrane-anchored protein galactosyltransferase (GT:UDP-galactose-β,1,4-galactosyltransferase. EC 2.4.1.22) ligated to polynucleotides encoding EGFP, ECFP, or EYFP. The polynucleotides encoding the resulting proteins were named GT-EGFP, GT-ECFP, and GT-EYFP, respectively.

Mitochondrial matrix fluorescent protein pH sensors were constructed by attaching polynucleotides encoding 12 amino acids at the amino terminus to the presequence of subunit IV of cytochrome c oxidase (Hutl et al, EMBO J. 4:2061-68 (1985) to a polynucleotide encoding the amino acid sequence Arg-Sea-Gly-Ile (SEQ ID NO: 18), which in turn was ligated to polynucleotides encoding ECFP or EYFP. These constructs were labeled ECFP-mito or EYFP-mito.

The constructs used to examine intracellular pH are summarized in FIG. 1.

Example 2 pH Titration of Fluroescent Sensor Proteins In Vitro

The pH sensitivity of the fluorescence of the proteins ECFP, EGFP, EYFP, GT-EGFP, and GT-EYFP was first examined.

Absorbance spectra were obtained in a Cary 3E spectrophotometer (Varian). For pH titration, a monochromator-equipped fluorometer (Spex Industries, NJ) and a 96-well microplate fluorometer (Cambridge Technology) were used. In the latter case the filters used for excitation were 482±10 (460±18 for ECFP) and for emission were 532±14. Filters were named as the center wavelength ± the half-bandwidth, both in nm. The solutions for cuvette titration contained 125 mM KCl, 20 mM NaCl, 0.5 mM CaCl₂, 0.5 mM MgCl₂, and 25 mM of one of the following buffers-acetate, Mes, Mops, Hepes, bicine, and Tris.

EYFP showed an acidification-dependent decrease in the absorbance peak at 514 nm and a concomitant increase in absorbance at 390 nm (FIG. 2A). The fluorescence emission (527-nm peak) and excitation spectra decreased with decreasing pH, but the fluorescence excitation spectrum showed no compensating increase at 390 nm. Therefore, the species absorbing at 390 nm was nonfluorescent. The apparent pKa (pK'a) of EYFP was 7.1 with a Hill coefficient (n) of 1.1 (FIG. 2B).

EGFP fluorescence also was quenched with decreasing pH. The pK'a of EGFP was 6.15, and n was 0.7.

The change in fluorescence of ECFP (Tyr66→Trp in the chromophore) with pH was smaller than that of EGFP or EYFP (pK'a 6.4, n, 0.6) (FIG. 2B). The fluorescence change was reversible in the pH range 5-8.5 for all three proteins, which covers the pH range of most subcellular compartments. These results demonstrate that the GFP variants EGFP, EYFP, and ECFP can be used as fluorescent protein pH sensors.

Example 3 Measurements of pH in the Cytosol and Nucleus Using Fluorescent Protein pH Sensors

HeLa cells and AT-20 cells grown on glass coverslips were transiently lipo-transfected (Lipofectin™, GIBCO) with polynucleotide constructs encoding EYFP.

Cells were imaged between 2 and 4 days after transfection at 22° C. with a cooled charge-coupled device camera (Photometrices, Tucson, Ariz.) as described in Miyawaki et al., Nature 388:882, (1997). The interference filters (Omega Optical and Chroma Technology, Brattleboro, Vt.) used for excitation and emission were 440±10 and 480±15 for ECFP; 480±15 and 535±22.5 for EGFP or EYFP. The dichroic mirrors were 455 DCLP for ECFP and 505 DCLP for EGFP or EYFP. Regions of interest were selected manually, and pixel intensities were spatially averaged after background subtraction. A binning of 2 was used to improve signal/noise and minimize photodamage and photoisomerization of EYFP. In the Cl-free bath solution, Na-D gluconate and K-D gluoconate substituted for NaCl and Hanks' balanced salt solution. High KCl buffer plus 5 μM each of the ionophores nigericin (Fluka) and monensin (Calbiochem) was used for in situ titrations in living cells. Cells were loaded with cytosolic pH indicators by incubation with 3 μM carboxy-SNARF/AM or BCECF/AM (Molecular Probes) for 45 minutes, then washed for 30 minutes, all at 22° C.

Fluorescence of HeLa cells transfected with the gene encoding EYFP was diffusely distributed in the cytosol and nucleus. This was expected for a protein of the size of GFP (27 kDa), which is small enough to pass through nuclear pores.

The fluorescence observed with EYFP was reversible. Perfusion with NH₄ Cl caused an increase in fluorescence (rise in pH), which reversed upon washing out the NH₄ Cl. Conversely, perfusion of lactate, which lowers pH, induced a decrease in fluorescence. The decrease in fluorescence was also reversible on wash-out.

Calibration of fluorescence intensity with pH in situ was accomplished with a mix of the alkali cation/H+ ionophores nigericin and monensin in bath solutions of defined pH and high K+. Fluorescence equilibrated within 1-4 minutes after each exchange of solution. These results demonstrate that EYFP, when present intracellularly, can report pH in the physiological range.

Example 4 Measurement of pH in the Mitochondrial Matrix Using Fluorescent Protein pH Sensors

To measure pH in the mitochondrial matrix using mutant GFP sensor proteins, HeLa cells and neonatal rat myocytes were transfected with the fluorescent protein pH sensor EYFP-mito. A Bio-Rad MRC-1000 confocal microscope was used for analysis of the targeted protein. Microscopy analysis revealed that the transfected cells showed a fluorescence pattern indistinguishable from that of the conventional mitochondrial dye rhodamine 123.

In situ pH titration was performed with nigericin/monensin as described in Example 3. Subsequent addition of the protonophore carbonylcyanide nt-chlorophenylhydrazone (CCCP) did not change the fluorescence intensity of the cells. This demonstrates that the nigericn/monensin treatment effectively collapsed the pH gradient(ApH)in the mitochondria.

The estimated pHm was 7.98±0.07 in HeLa cells (n=17 cells, from six experiments). Similar pH values were obtained in a HeLa cell line stably expressing EYFP-mito. Resting pH did not change by superfusion of cells with medium 10 mM glucose, which would provide cells with an oxidizable substrate, but 10 mM lactate plus 1 mM pyruvate caused an acidification, which reversed on washout. This can be accounted for by diffusion of protonated acid or by cotransport of pyruvate⁻ /H⁺ through the inner mitochondrial membrane. The protonophore CCCP rapidly induced an acidification of mitochondria to about pH 7.

Example 5 Measurement of pH in the Golgi Lumen Using Fluorescent Protein pH Sensors

The type II membrane-anchored protein galactosyltransferase (GT:UDP-galactose-β,1,4-galactosyltransferase. EC 2.4.1.22) has been used as a marker of the trans cisternae of the Golgi apparatus (Roth et al., J. Cell Biol. 93:223-29, (1982)). Accordingly, polynucleotide constructs encoding portions of the GT protein fused to the mutant GFP proteins were constructed as described in Example 1 in order to use the GT sequence to target the fluorescent protein pH sensor to the endoplasmic reticulum.

The pH of the Golgi lumen was measured by transfecting HeLa or AT-20 cells with the constructs GT-ECFP, GT-EGFP, or GT-EYFP. Bright juxtanuclear fluorescence was observed, with little increase in diffuse staining above autofluorescnce in most cells.

The fluorescence pattern was examined further in double-labeling experiments using rabbit polyclonal α-mannosidase II (α-manII) antibody. Double labeling fluorescence was performed as described by McCaffery et al., Methods Enzymol. 257:259-279 (1995). The α-manII antibody was prepared as described in Velasco et al., J. Cell Biol. 122:39-51 (1993). In the double-staining experiments, it was observed that labeling of the medial trans-Golgi marker α-manII overlapped with GT-EYFP fluorescence.

α-manII was also fused with ECFP, and the pattern of fluorescence obtained upon transfection of the gene was indistinguishable from that of GT-EYFP by light microcopy.

To identify the subcellular localization of GT-EYFP at higher resolution, immunogold electron microscopy was performed on ultra-thin cryosections by using antibodies against GFP. Immunogold labeling of ultra-thin sections was performed as described by McCaffery et al., supra, using rabbit polyclonal anti-GFP antibody or a monoclonal anti-TGN38 antibody.

In double-labeling experiments, GT-EYFP was found in the medial and trans Golgi, although endogenous GT is present in trans Golgi membranes. The difference in localization may occur as a result of overexpression of the GT-EYFP protein.

When protein TGN38 was used as a trans-Golgi network (TGN) marker, its immunogold localization pattern was found to overlap with that of GT-EYFP in the medial/trans-Golgi membranes. The localization data demonstrate that GT-EYFP labels the medial/trans Golgi. Thus, GT-EYFP can be used to identify the pH of this organelle.

The pH titration of GT-EYFP fluorescence in the Golgi region of the cells after treatment with nigericin/monensin was in good agreement with that of EYFP in vitro (see Example 2). Resting pH in HeLa cells was on average 6.58 (range 6.4-6.81, n=30 cells, 9 experiments). These results also demonstrate that neither fusion with GT nor the composition of the Golgi lumen affects the pH sensitivity of EYFP. Thus, Golgi-targeted EYFP can be used as a local pH indicator.

The effect of various treatments on the pH of the Golgi was next examined using Golgi-targeted EYFP.

The pH gradient across the Golgi membrane is maintained by the electrogenic ATP-dependent H⁺ pump (V-ATPase). The V-ATPase generates a ΔpH (acidic inside) and Δ104 (positive inside), which opposes further H⁺ transport. The movement of counter-ions, Cl⁻ in (or K⁺ out), with H⁺ uptake would shunt the Δψ, allowing a larger ΔpH to be generated. These mechanisms were investigated in intact single HeLa cells transfected with GT-EYFP.

The macrolide antibiotic bafilomycin Al has been shown to be a potent inhibitor of vacuolar type H⁺ ATPases (V type). In Hela cells expressing GT-EYFP, bafilomycin Al (0.2 μM) increased pH_(G) by about 0.6 units, to pH 7.16 (range 7.02-7.37, n=12 cells. This suggests that the H⁺ pump compensates for a positive H+ efflux or leak. The initial rate of Golgi alkalinization by bafilomycin Al was 0.52 pH units per minute (range 0.3-0.77, n=12 cells), faster than that reported for other acidic compartments such as macrophage phagosomes (0.09 pH/min). Similar results regarding resting pHG and alkalinization by bafilomycin Al where obtained when HeLa cells were transfected with GT-EGFP. Calibration of GT-EGFP in situ also mirrored its in vitro titration (FIG. 1B). Thus, both EGFP and EYFP are suitable Golgi pH indicators.

Example 6 Measuring Intracellular pH with Two Fluorescent Protein Protein Sensors

Quantitative measurements of fluorescence with nonratiometric indicators can suffer from artifacts as a result of cell movement or focusing. To correct for these effects, the cyan-emitting mutant GT-ECFP was co-transfected into cells along with GT-EYFP. ECFP has excitation and emission peaks that can be separated from those of EYFP by appropriate filters. In addition, ECFP is less pH-sensitive than EYFP (see FIG. 2B).

FIG. 3A demonstrates that the fluorescence of ECFP changed less than that of EYFP during the course of the experiment. Although the ratio of EYFP to ECFP emission varied between cells, probably reflecting a different concentration of GT-EYFP and GT-ECFP in the Golgi lumen, it changed with pH as expected (FIG. 3B). Bafilomcin Al raised the GT-EYFP/GT-ECFP emission ratio, i.e, it raised pHG.

Other Embodiments

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

    __________________________________________________________________________     #             SEQUENCE LISTING                                                    - -  - - <160> NUMBER OF SEQ ID NOS: 18                                        - - <210> SEQ ID NO 1                                                         <211> LENGTH: 716                                                              <212> TYPE: DNA                                                                <213> ORGANISM: Aequorea victoria                                              <220> FEATURE:                                                                 <221> NAME/KEY: CDS                                                            <222> LOCATION: (1)...(714)                                                    <223> OTHER INFORMATION: Green fluorescent protein                              - - <400> SEQUENCE: 1                                                          - - atg agt aaa gga gaa gaa ctt ttc act gga gt - #t gtc cca att ctt         gtt       48                                                                     Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Va - #l Val Pro Ile Leu Val            1               5  - #                 10 - #                 15               - - gaa tta gat ggt gat gtt aat ggg cac aaa tt - #t tct gtc agt gga gag            96                                                                        Glu Leu Asp Gly Asp Val Asn Gly His Lys Ph - #e Ser Val Ser Gly Glu                         20     - #             25     - #             30                   - - ggt gaa ggt gat gca aca tac gga aaa ctt ac - #c ctt aaa ttt att tgc           144                                                                        Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Th - #r Leu Lys Phe Ile Cys                     35         - #         40         - #         45                       - - act act gga aaa cta cct gtt cca tgg cca ac - #a ctt gtc act act ttc           192                                                                        Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Th - #r Leu Val Thr Thr Phe                 50             - #     55             - #     60                           - - tct tat ggt gtt caa tgc ttt tca aga tac cc - #a gat cat atg aaa cgg           240                                                                        Ser Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pr - #o Asp His Met Lys Arg             65                 - # 70                 - # 75                 - # 80        - - cat gac ttt ttc aag agt gcc atg ccc gaa gg - #t tat gta cag gaa aga           288                                                                        His Asp Phe Phe Lys Ser Ala Met Pro Glu Gl - #y Tyr Val Gln Glu Arg                             85 - #                 90 - #                 95               - - act ata ttt ttc aaa gat gac ggg aac tac aa - #g aca cgt gct gaa gtc           336                                                                        Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Ly - #s Thr Arg Ala Glu Val                        100      - #           105      - #           110                   - - aag ttt gaa ggt gat acc ctt gtt aat aga at - #c gag tta aaa ggt att           384                                                                        Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Il - #e Glu Leu Lys Gly Ile                    115          - #       120          - #       125                       - - gat ttt aaa gaa gat gga aac att ctt gga ca - #c aaa ttg gaa tac aac           432                                                                        Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly Hi - #s Lys Leu Glu Tyr Asn                130              - #   135              - #   140                           - - tat aac tca cac aat gta tac atc atg gca ga - #c aaa caa aag aat gga           480                                                                        Tyr Asn Ser His Asn Val Tyr Ile Met Ala As - #p Lys Gln Lys Asn Gly            145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - atc aaa gtt aac ttc aaa att aga cac aac at - #t gaa gat gga agc         gtt      528                                                                     Ile Lys Val Asn Phe Lys Ile Arg His Asn Il - #e Glu Asp Gly Ser Val                           165  - #               170  - #               175               - - caa cta gca gac cat tat caa caa aat act cc - #a att ggc gat ggc cct           576                                                                        Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pr - #o Ile Gly Asp Gly Pro                        180      - #           185      - #           190                   - - gtc ctt tta cca gac aac cat tac ctg tcc ac - #a caa tct gcc ctt tcg           624                                                                        Val Leu Leu Pro Asp Asn His Tyr Leu Ser Th - #r Gln Ser Ala Leu Ser                    195          - #       200          - #       205                       - - aaa gat ccc aac gaa aag aga gac cac atg gt - #c ctt ctt gag ttt gta           672                                                                        Lys Asp Pro Asn Glu Lys Arg Asp His Met Va - #l Leu Leu Glu Phe Val                210              - #   215              - #   220                           - - aca gct gct ggg att aca cat ggc atg gat ga - #a cta tac aaa                  - # 714                                                                     Thr Ala Ala Gly Ile Thr His Gly Met Asp Gl - #u Leu Tyr Lys                    225                 2 - #30                 2 - #35                             - - ta                  - #                  - #                  - #                  716                                                                    - -  - - <210> SEQ ID NO 2                                                    <211> LENGTH: 238                                                              <212> TYPE: PRT                                                                <213> ORGANISM: Aequorea victoria                                               - - <400> SEQUENCE: 2                                                          - - Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Va - #l Val Pro Ile Leu Val        1               5  - #                10  - #                15                - - Glu Leu Asp Gly Asp Val Asn Gly His Lys Ph - #e Ser Val Ser Gly Glu                   20      - #            25      - #            30                    - - Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Th - #r Leu Lys Phe Ile Cys               35          - #        40          - #        45                        - - Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Th - #r Leu Val Thr Thr Phe           50              - #    55              - #    60                            - - Ser Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pr - #o Asp His Met Lys Arg       65                  - #70                  - #75                  - #80         - - His Asp Phe Phe Lys Ser Ala Met Pro Glu Gl - #y Tyr Val Gln Glu Arg                       85  - #                90  - #                95                - - Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Ly - #s Thr Arg Ala Glu Val                   100      - #           105      - #           110                   - - Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Il - #e Glu Leu Lys Gly Ile               115          - #       120          - #       125                       - - Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly Hi - #s Lys Leu Glu Tyr Asn           130              - #   135              - #   140                           - - Tyr Asn Ser His Asn Val Tyr Ile Met Ala As - #p Lys Gln Lys Asn Gly       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Ile Lys Val Asn Phe Lys Ile Arg His Asn Il - #e Glu Asp Gly Ser         Val                                                                                              165  - #               170  - #               175              - - Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pr - #o Ile Gly Asp Gly Pro                   180      - #           185      - #           190                   - - Val Leu Leu Pro Asp Asn His Tyr Leu Ser Th - #r Gln Ser Ala Leu Ser               195          - #       200          - #       205                       - - Lys Asp Pro Asn Glu Lys Arg Asp His Met Va - #l Leu Leu Glu Phe Val           210              - #   215              - #   220                           - - Thr Ala Ala Gly Ile Thr His Gly Met Asp Gl - #u Leu Tyr Lys               225                 2 - #30                 2 - #35                             - -  - - <210> SEQ ID NO 3                                                    <211> LENGTH: 720                                                              <212> TYPE: DNA                                                                <213> ORGANISM: Aequorea victoria                                              <220> FEATURE:                                                                 <221> NAME/KEY: CDS                                                            <222> LOCATION: (1)...(717)                                                    <223> OTHER INFORMATION: EGFP                                                   - - <400> SEQUENCE: 3                                                          - - atg gtg agc aag ggc gag gag ctg ttc acc gg - #g gtg gtg ccc atc ctg            48                                                                        Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gl - #y Val Val Pro Ile Leu             1               5  - #                 10 - #                 15               - - gtc gag ctg gac ggc gac gta aac ggc cac ag - #g ttc agc gtg tcc ggc            96                                                                        Val Glu Leu Asp Gly Asp Val Asn Gly His Ar - #g Phe Ser Val Ser Gly                         20     - #             25     - #             30                   - - gag ggc gag ggc gat gcc acc tac ggc aag ct - #g acc ctg aag ttc atc           144                                                                        Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Le - #u Thr Leu Lys Phe Ile                     35         - #         40         - #         45                       - - tgc acc acc ggc aag ctg ccc gtg ccc tgg cc - #c acc ctc gtg acc acc           192                                                                        Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pr - #o Thr Leu Val Thr Thr                 50             - #     55             - #     60                           - - ctg acc tac ggc gtg cag tgc ttc agc cgc ta - #c ccc gac cac atg aag           240                                                                        Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Ty - #r Pro Asp His Met Lys             65                 - # 70                 - # 75                 - # 80        - - cag cac gac ttc ttc aag tcc gcc atg ccc ga - #a ggc tac gtc cag gag           288                                                                        Gln His Asp Phe Phe Lys Ser Ala Met Pro Gl - #u Gly Tyr Val Gln Glu                             85 - #                 90 - #                 95               - - cgc acc atc ttc ttc aag gac gac ggc aac ta - #c aag acc cgc gcc gag           336                                                                        Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Ty - #r Lys Thr Arg Ala Glu                        100      - #           105      - #           110                   - - gtg aag ttc gag ggc gac acc ctg gtg aac cg - #c atc gag ctg aag ggc           384                                                                        Val Lys Phe Glu Gly Asp Thr Leu Val Asn Ar - #g Ile Glu Leu Lys Gly                    115          - #       120          - #       125                       - - atc gac ttc aag gag gac ggc aac atc ctg gg - #g cac aag ctg gag tac           432                                                                        Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gl - #y His Lys Leu Glu Tyr                130              - #   135              - #   140                           - - aac tac aac agc cac aac gtc tat atc atg gc - #c gac aag cag aag aac           480                                                                        Asn Tyr Asn Ser His Asn Val Tyr Ile Met Al - #a Asp Lys Gln Lys Asn            145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - ggc atc aag gtg aac ttc aag atc cgc cac aa - #c atc gag gac ggc         agc      528                                                                     Gly Ile Lys Val Asn Phe Lys Ile Arg His As - #n Ile Glu Asp Gly Ser                           165  - #               170  - #               175               - - gtg cag ctc gcc gac cac tac cag cag aac ac - #c ccc atc ggc gac ggc           576                                                                        Val Gln Leu Ala Asp His Tyr Gln Gln Asn Th - #r Pro Ile Gly Asp Gly                        180      - #           185      - #           190                   - - ccc gtg ctg ctg ccc gac aac cac tac ctg ag - #c acc cag tcc gcc ctg           624                                                                        Pro Val Leu Leu Pro Asp Asn His Tyr Leu Se - #r Thr Gln Ser Ala Leu                    195          - #       200          - #       205                       - - agc aaa gac ccc aac gag aag cgc gat cac at - #g gtc ctg ctg gag ttc           672                                                                        Ser Lys Asp Pro Asn Glu Lys Arg Asp His Me - #t Val Leu Leu Glu Phe                210              - #   215              - #   220                           - - gtg acc gcc gcc ggg atc act ctc ggc atg ga - #c gag ctg tac aag               71 - #7                                                                    Val Thr Ala Ala Gly Ile Thr Leu Gly Met As - #p Glu Leu Tyr Lys                225                 2 - #30                 2 - #35                             - - taa                  - #                  - #                  - #                 720                                                                    - -  - - <210> SEQ ID NO 4                                                    <211> LENGTH: 239                                                              <212> TYPE: PRT                                                                <213> ORGANISM: Aequorea victoria                                               - - <400> SEQUENCE: 4                                                          - - Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gl - #y Val Val Pro Ile Leu        1               5  - #                10  - #                15                - - Val Glu Leu Asp Gly Asp Val Asn Gly His Ar - #g Phe Ser Val Ser Gly                   20      - #            25      - #            30                    - - Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Le - #u Thr Leu Lys Phe Ile               35          - #        40          - #        45                        - - Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pr - #o Thr Leu Val Thr Thr           50              - #    55              - #    60                            - - Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Ty - #r Pro Asp His Met Lys       65                  - #70                  - #75                  - #80         - - Gln His Asp Phe Phe Lys Ser Ala Met Pro Gl - #u Gly Tyr Val Gln Glu                       85  - #                90  - #                95                - - Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Ty - #r Lys Thr Arg Ala Glu                   100      - #           105      - #           110                   - - Val Lys Phe Glu Gly Asp Thr Leu Val Asn Ar - #g Ile Glu Leu Lys Gly               115          - #       120          - #       125                       - - Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gl - #y His Lys Leu Glu Tyr           130              - #   135              - #   140                           - - Asn Tyr Asn Ser His Asn Val Tyr Ile Met Al - #a Asp Lys Gln Lys Asn       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Gly Ile Lys Val Asn Phe Lys Ile Arg His As - #n Ile Glu Asp Gly         Ser                                                                                              165  - #               170  - #               175              - - Val Gln Leu Ala Asp His Tyr Gln Gln Asn Th - #r Pro Ile Gly Asp Gly                   180      - #           185      - #           190                   - - Pro Val Leu Leu Pro Asp Asn His Tyr Leu Se - #r Thr Gln Ser Ala Leu               195          - #       200          - #       205                       - - Ser Lys Asp Pro Asn Glu Lys Arg Asp His Me - #t Val Leu Leu Glu Phe           210              - #   215              - #   220                           - - Val Thr Ala Ala Gly Ile Thr Leu Gly Met As - #p Glu Leu Tyr Lys           225                 2 - #30                 2 - #35                             - -  - - <210> SEQ ID NO 5                                                    <211> LENGTH: 720                                                              <212> TYPE: DNA                                                                <213> ORGANISM: Aequorea victoria                                              <220> FEATURE:                                                                 <221> NAME/KEY: CDS                                                            <222> LOCATION: (1)...(717)                                                    <223> OTHER INFORMATION: EYFP                                                   - - <400> SEQUENCE: 5                                                          - - atg gtg agc aag ggc gag gag ctg ttc acc gg - #g gtg gtg ccc atc ctg            48                                                                        Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gl - #y Val Val Pro Ile Leu             1               5  - #                 10 - #                 15               - - gtc gag ctg gac ggc gac gta aac ggc cac ag - #g ttc agc gtg tcc ggc            96                                                                        Val Glu Leu Asp Gly Asp Val Asn Gly His Ar - #g Phe Ser Val Ser Gly                         20     - #             25     - #             30                   - - gag ggc gag ggc gat gcc acc tac ggc aag ct - #g acc ctg aag ttc atc           144                                                                        Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Le - #u Thr Leu Lys Phe Ile                     35         - #         40         - #         45                       - - tgc acc acc ggc aag ctg ccc gtg ccc tgg cc - #c acc ctc gtg acc acc           192                                                                        Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pr - #o Thr Leu Val Thr Thr                 50             - #     55             - #     60                           - - ttc ggc tac ggc gtg cag tgc ttc gcc cgc ta - #c ccc gac cac atg aag           240                                                                        Phe Gly Tyr Gly Val Gln Cys Phe Ala Arg Ty - #r Pro Asp His Met Lys             65                 - # 70                 - # 75                 - # 80        - - cag cac gac ttc ttc aag tcc gcc atg ccc ga - #a ggc tac gtc cag gag           288                                                                        Gln His Asp Phe Phe Lys Ser Ala Met Pro Gl - #u Gly Tyr Val Gln Glu                             85 - #                 90 - #                 95               - - cgc acc atc ttc ttc aag gac gac ggc aac ta - #c aag acc cgc gcc gag           336                                                                        Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Ty - #r Lys Thr Arg Ala Glu                        100      - #           105      - #           110                   - - gtg aag ttc gag ggc gac acc ctg gtg aac cg - #c atc gag ctg aag ggc           384                                                                        Val Lys Phe Glu Gly Asp Thr Leu Val Asn Ar - #g Ile Glu Leu Lys Gly                    115          - #       120          - #       125                       - - atc gac ttc aag gag gac ggc aac atc ctg gg - #g cac aag ctg gag tac           432                                                                        Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gl - #y His Lys Leu Glu Tyr                130              - #   135              - #   140                           - - aac tac aac agc cac aac gtc tat atc atg gc - #c gac aag cag aag aac           480                                                                        Asn Tyr Asn Ser His Asn Val Tyr Ile Met Al - #a Asp Lys Gln Lys Asn            145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - ggc atc aag gtg aac ttc aag atc cgc cac aa - #c atc gag gac ggc         agc      528                                                                     Gly Ile Lys Val Asn Phe Lys Ile Arg His As - #n Ile Glu Asp Gly Ser                           165  - #               170  - #               175               - - gtg cag ctc gcc gac cac tac cag cag aac ac - #c ccc atc ggc gac ggc           576                                                                        Val Gln Leu Ala Asp His Tyr Gln Gln Asn Th - #r Pro Ile Gly Asp Gly                        180      - #           185      - #           190                   - - ccc gtg ctg ctg ccc gac aac cac tac ctg ag - #c tac cag tcc gcc ctg           624                                                                        Pro Val Leu Leu Pro Asp Asn His Tyr Leu Se - #r Tyr Gln Ser Ala Leu                    195          - #       200          - #       205                       - - agc aaa gac ccc aac gag aag cgc gat cac at - #g gtc ctg ctg gag ttc           672                                                                        Ser Lys Asp Pro Asn Glu Lys Arg Asp His Me - #t Val Leu Leu Glu Phe                210              - #   215              - #   220                           - - gtg acc gcc gcc ggg atc act ctc ggc atg ga - #c gag ctg tac aag               71 - #7                                                                    Val Thr Ala Ala Gly Ile Thr Leu Gly Met As - #p Glu Leu Tyr Lys                225                 2 - #30                 2 - #35                             - - taa                  - #                  - #                  - #                 720                                                                    - -  - - <210> SEQ ID NO 6                                                    <211> LENGTH: 239                                                              <212> TYPE: PRT                                                                <213> ORGANISM: Aequorea victoria                                               - - <400> SEQUENCE: 6                                                          - - Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gl - #y Val Val Pro Ile Leu        1               5  - #                10  - #                15                - - Val Glu Leu Asp Gly Asp Val Asn Gly His Ar - #g Phe Ser Val Ser Gly                   20      - #            25      - #            30                    - - Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Le - #u Thr Leu Lys Phe Ile               35          - #        40          - #        45                        - - Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pr - #o Thr Leu Val Thr Thr           50              - #    55              - #    60                            - - Phe Gly Tyr Gly Val Gln Cys Phe Ala Arg Ty - #r Pro Asp His Met Lys       65                  - #70                  - #75                  - #80         - - Gln His Asp Phe Phe Lys Ser Ala Met Pro Gl - #u Gly Tyr Val Gln Glu                       85  - #                90  - #                95                - - Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Ty - #r Lys Thr Arg Ala Glu                   100      - #           105      - #           110                   - - Val Lys Phe Glu Gly Asp Thr Leu Val Asn Ar - #g Ile Glu Leu Lys Gly               115          - #       120          - #       125                       - - Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gl - #y His Lys Leu Glu Tyr           130              - #   135              - #   140                           - - Asn Tyr Asn Ser His Asn Val Tyr Ile Met Al - #a Asp Lys Gln Lys Asn       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Gly Ile Lys Val Asn Phe Lys Ile Arg His As - #n Ile Glu Asp Gly         Ser                                                                                              165  - #               170  - #               175              - - Val Gln Leu Ala Asp His Tyr Gln Gln Asn Th - #r Pro Ile Gly Asp Gly                   180      - #           185      - #           190                   - - Pro Val Leu Leu Pro Asp Asn His Tyr Leu Se - #r Tyr Gln Ser Ala Leu               195          - #       200          - #       205                       - - Ser Lys Asp Pro Asn Glu Lys Arg Asp His Me - #t Val Leu Leu Glu Phe           210              - #   215              - #   220                           - - Val Thr Ala Ala Gly Ile Thr Leu Gly Met As - #p Glu Leu Tyr Lys           225                 2 - #30                 2 - #35                             - -  - - <210> SEQ ID NO 7                                                    <211> LENGTH: 720                                                              <212> TYPE: DNA                                                                <213> ORGANISM: Aequorea victoria                                              <220> FEATURE:                                                                 <221> NAME/KEY: CDS                                                            <222> LOCATION: (1)...(717)                                                    <223> OTHER INFORMATION: ECFP                                                   - - <400> SEQUENCE: 7                                                          - - atg gtg agc aag ggc gag gag ctg ttc acc gg - #g gtg gtg ccc atc ctg            48                                                                        Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gl - #y Val Val Pro Ile Leu             1               5  - #                 10 - #                 15               - - gtc gag ctg gac ggc gac gta aac ggc cac ag - #g ttc agc gtg tcc ggc            96                                                                        Val Glu Leu Asp Gly Asp Val Asn Gly His Ar - #g Phe Ser Val Ser Gly                         20     - #             25     - #             30                   - - gag ggc gag ggc gat gcc acc tac ggc aag ct - #g acc ctg aag ttc atc           144                                                                        Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Le - #u Thr Leu Lys Phe Ile                     35         - #         40         - #         45                       - - tgc acc acc ggc aag ctg ccc gtg ccc tgg cc - #c acc ctc gtg acc acc           192                                                                        Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pr - #o Thr Leu Val Thr Thr                 50             - #     55             - #     60                           - - ctg acc tgg ggc gtg cag tgc ttc agc cgc ta - #c ccc gac cac atg aag           240                                                                        Leu Thr Trp Gly Val Gln Cys Phe Ser Arg Ty - #r Pro Asp His Met Lys             65                 - # 70                 - # 75                 - # 80        - - cag cac gac ttc ttc aag tcc gcc atg ccc ga - #a ggc tac gtc cag gag           288                                                                        Gln His Asp Phe Phe Lys Ser Ala Met Pro Gl - #u Gly Tyr Val Gln Glu                             85 - #                 90 - #                 95               - - cgc acc atc ttc ttc aag gac gac ggc aac ta - #c aag acc cgc gcc gag           336                                                                        Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Ty - #r Lys Thr Arg Ala Glu                        100      - #           105      - #           110                   - - gtg aag ttc gag ggc gac acc ctg gtg aac cg - #c atc gag ctg aag ggc           384                                                                        Val Lys Phe Glu Gly Asp Thr Leu Val Asn Ar - #g Ile Glu Leu Lys Gly                    115          - #       120          - #       125                       - - atc gac ttc aag gag gac ggc aac atc ctg gg - #g cac aag ctg gag tac           432                                                                        Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gl - #y His Lys Leu Glu Tyr                130              - #   135              - #   140                           - - aac tac atc agc cac aac gtc tat atc acc gc - #c gac aag cag aag aac           480                                                                        Asn Tyr Ile Ser His Asn Val Tyr Ile Thr Al - #a Asp Lys Gln Lys Asn            145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - ggc atc aag gcc cac ttc aag atc cgc cac aa - #c atc gag gac ggc         agc      528                                                                     Gly Ile Lys Ala His Phe Lys Ile Arg His As - #n Ile Glu Asp Gly Ser                           165  - #               170  - #               175               - - gtg cag ctc gcc gac cac tac cag cag aac ac - #c ccc atc ggc gac ggc           576                                                                        Val Gln Leu Ala Asp His Tyr Gln Gln Asn Th - #r Pro Ile Gly Asp Gly                        180      - #           185      - #           190                   - - ccc gtg ctg ctg ccc gac aac cac tac ctg ag - #c acc cag tcc gcc ctg           624                                                                        Pro Val Leu Leu Pro Asp Asn His Tyr Leu Se - #r Thr Gln Ser Ala Leu                    195          - #       200          - #       205                       - - agc aaa gac ccc aac gag aag cgc gat cac at - #g gtc ctg ctg gag ttc           672                                                                        Ser Lys Asp Pro Asn Glu Lys Arg Asp His Me - #t Val Leu Leu Glu Phe                210              - #   215              - #   220                           - - gtg acc gcc gcc ggg atc act ctc ggc atg ga - #c gag ctg tac aag               71 - #7                                                                    Val Thr Ala Ala Gly Ile Thr Leu Gly Met As - #p Glu Leu Tyr Lys                225                 2 - #30                 2 - #35                             - - taa                  - #                  - #                  - #                 720                                                                    - -  - - <210> SEQ ID NO 8                                                    <211> LENGTH: 239                                                              <212> TYPE: PRT                                                                <213> ORGANISM: Aequorea victoria                                               - - <400> SEQUENCE: 8                                                          - - Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gl - #y Val Val Pro Ile Leu        1               5  - #                10  - #                15                - - Val Glu Leu Asp Gly Asp Val Asn Gly His Ar - #g Phe Ser Val Ser Gly                   20      - #            25      - #            30                    - - Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Le - #u Thr Leu Lys Phe Ile               35          - #        40          - #        45                        - - Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pr - #o Thr Leu Val Thr Thr           50              - #    55              - #    60                            - - Leu Thr Trp Gly Val Gln Cys Phe Ser Arg Ty - #r Pro Asp His Met Lys       65                  - #70                  - #75                  - #80         - - Gln His Asp Phe Phe Lys Ser Ala Met Pro Gl - #u Gly Tyr Val Gln Glu                       85  - #                90  - #                95                - - Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Ty - #r Lys Thr Arg Ala Glu                   100      - #           105      - #           110                   - - Val Lys Phe Glu Gly Asp Thr Leu Val Asn Ar - #g Ile Glu Leu Lys Gly               115          - #       120          - #       125                       - - Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gl - #y His Lys Leu Glu Tyr           130              - #   135              - #   140                           - - Asn Tyr Ile Ser His Asn Val Tyr Ile Thr Al - #a Asp Lys Gln Lys Asn       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Gly Ile Lys Ala His Phe Lys Ile Arg His As - #n Ile Glu Asp Gly         Ser                                                                                              165  - #               170  - #               175              - - Val Gln Leu Ala Asp His Tyr Gln Gln Asn Th - #r Pro Ile Gly Asp Gly                   180      - #           185      - #           190                   - - Pro Val Leu Leu Pro Asp Asn His Tyr Leu Se - #r Thr Gln Ser Ala Leu               195          - #       200          - #       205                       - - Ser Lys Asp Pro Asn Glu Lys Arg Asp His Me - #t Val Leu Leu Glu Phe           210              - #   215              - #   220                           - - Val Thr Ala Ala Gly Ile Thr Leu Gly Met As - #p Glu Leu Tyr Lys           225                 2 - #30                 2 - #35                             - -  - - <210> SEQ ID NO 9                                                    <211> LENGTH: 720                                                              <212> TYPE: DNA                                                                <213> ORGANISM: Aequorea victoria                                              <220> FEATURE:                                                                 <221> NAME/KEY: CDS                                                            <222> LOCATION: (1)...(717)                                                    <223> OTHER INFORMATION: EYFP-V68L/Q69K                                         - - <400> SEQUENCE: 9                                                          - - atg gtg agc aag ggc gag gag ctg ttc acc gg - #g gtg gtg ccc atc ctg            48                                                                        Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gl - #y Val Val Pro Ile Leu             1               5  - #                 10 - #                 15               - - gtc gag ctg gac ggc gac gta aac ggc cac ag - #g ttc agc gtg tcc ggc            96                                                                        Val Glu Leu Asp Gly Asp Val Asn Gly His Ar - #g Phe Ser Val Ser Gly                         20     - #             25     - #             30                   - - gag ggc gag ggc gat gcc acc tac ggc aag ct - #g acc ctg aag ttc atc           144                                                                        Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Le - #u Thr Leu Lys Phe Ile                     35         - #         40         - #         45                       - - tgc acc acc ggc aag ctg ccc gtg ccc tgg cc - #c acc ctc gtg acc acc           192                                                                        Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pr - #o Thr Leu Val Thr Thr                 50             - #     55             - #     60                           - - ttc ggc tac ggc ctg aag tgc ttc gcc cgc ta - #c ccc gac cac atg aag           240                                                                        Phe Gly Tyr Gly Leu Lys Cys Phe Ala Arg Ty - #r Pro Asp His Met Lys             65                 - # 70                 - # 75                 - # 80        - - cag cac gac ttc ttc aag tcc gcc atg ccc ga - #a ggc tac gtc cag gag           288                                                                        Gln His Asp Phe Phe Lys Ser Ala Met Pro Gl - #u Gly Tyr Val Gln Glu                             85 - #                 90 - #                 95               - - cgc acc atc ttc ttc aag gac gac ggc aac ta - #c aag acc cgc gcc gag           336                                                                        Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Ty - #r Lys Thr Arg Ala Glu                        100      - #           105      - #           110                   - - gtg aag ttc gag ggc gac acc ctg gtg aac cg - #c atc gag ctg aag ggc           384                                                                        Val Lys Phe Glu Gly Asp Thr Leu Val Asn Ar - #g Ile Glu Leu Lys Gly                    115          - #       120          - #       125                       - - atc gac ttc aag gag gac ggc aac atc ctg gg - #g cac aag ctg gag tac           432                                                                        Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gl - #y His Lys Leu Glu Tyr                130              - #   135              - #   140                           - - aac tac aac agc cac aac gtc tat atc atg gc - #c gac aag cag aag aac           480                                                                        Asn Tyr Asn Ser His Asn Val Tyr Ile Met Al - #a Asp Lys Gln Lys Asn            145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - ggc atc aag gtg aac ttc aag atc cgc cac aa - #c atc gag gac ggc         agc      528                                                                     Gly Ile Lys Val Asn Phe Lys Ile Arg His As - #n Ile Glu Asp Gly Ser                           165  - #               170  - #               175               - - gtg cag ctc gcc gac cac tac cag cag aac ac - #c ccc atc ggc gac ggc           576                                                                        Val Gln Leu Ala Asp His Tyr Gln Gln Asn Th - #r Pro Ile Gly Asp Gly                        180      - #           185      - #           190                   - - ccc gtg ctg ctg ccc gac aac cac tac ctg ag - #c tac cag tcc gcc ctg           624                                                                        Pro Val Leu Leu Pro Asp Asn His Tyr Leu Se - #r Tyr Gln Ser Ala Leu                    195          - #       200          - #       205                       - - agc aaa gac ccc aac gag aag cgc gat cac at - #g gtc ctg ctg gag ttc           672                                                                        Ser Lys Asp Pro Asn Glu Lys Arg Asp His Me - #t Val Leu Leu Glu Phe                210              - #   215              - #   220                           - - gtg acc gcc gcc ggg atc act ctc ggc atg ga - #c gag ctg tac aag               71 - #7                                                                    Val Thr Ala Ala Gly Ile Thr Leu Gly Met As - #p Glu Leu Tyr Lys                225                 2 - #30                 2 - #35                             - - taa                  - #                  - #                  - #                 720                                                                    - -  - - <210> SEQ ID NO 10                                                   <211> LENGTH: 239                                                              <212> TYPE: PRT                                                                <213> ORGANISM: Aequorea victoria                                               - - <400> SEQUENCE: 10                                                         - - Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gl - #y Val Val Pro Ile Leu        1               5  - #                10  - #                15                - - Val Glu Leu Asp Gly Asp Val Asn Gly His Ar - #g Phe Ser Val Ser Gly                   20      - #            25      - #            30                    - - Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Le - #u Thr Leu Lys Phe Ile               35          - #        40          - #        45                        - - Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pr - #o Thr Leu Val Thr Thr           50              - #    55              - #    60                            - - Phe Gly Tyr Gly Leu Lys Cys Phe Ala Arg Ty - #r Pro Asp His Met Lys       65                  - #70                  - #75                  - #80         - - Gln His Asp Phe Phe Lys Ser Ala Met Pro Gl - #u Gly Tyr Val Gln Glu                       85  - #                90  - #                95                - - Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Ty - #r Lys Thr Arg Ala Glu                   100      - #           105      - #           110                   - - Val Lys Phe Glu Gly Asp Thr Leu Val Asn Ar - #g Ile Glu Leu Lys Gly               115          - #       120          - #       125                       - - Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gl - #y His Lys Leu Glu Tyr           130              - #   135              - #   140                           - - Asn Tyr Asn Ser His Asn Val Tyr Ile Met Al - #a Asp Lys Gln Lys Asn       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Gly Ile Lys Val Asn Phe Lys Ile Arg His As - #n Ile Glu Asp Gly         Ser                                                                                              165  - #               170  - #               175              - - Val Gln Leu Ala Asp His Tyr Gln Gln Asn Th - #r Pro Ile Gly Asp Gly                   180      - #           185      - #           190                   - - Pro Val Leu Leu Pro Asp Asn His Tyr Leu Se - #r Tyr Gln Ser Ala Leu               195          - #       200          - #       205                       - - Ser Lys Asp Pro Asn Glu Lys Arg Asp His Me - #t Val Leu Leu Glu Phe           210              - #   215              - #   220                           - - Val Thr Ala Ala Gly Ile Thr Leu Gly Met As - #p Glu Leu Tyr Lys           225                 2 - #30                 2 - #35                             - -  - - <210> SEQ ID NO 11                                                   <211> LENGTH: 768                                                              <212> TYPE: DNA                                                                <213> ORGANISM: Aequorea victoria                                              <220> FEATURE:                                                                 <221> NAME/KEY: CDS                                                            <222> LOCATION: (1)...(765)                                                    <223> OTHER INFORMATION: ECFP-mito                                              - - <400> SEQUENCE: 11                                                         - - atg ctg agc ctg cgc cag agc atc cgc ttc tt - #c aag cgc agc ggc atc            48                                                                        Met Leu Ser Leu Arg Gln Ser Ile Arg Phe Ph - #e Lys Arg Ser Gly Ile             1               5  - #                 10 - #                 15               - - atg gtg agc aag ggc gag gag ctg ttc acc gg - #g gtg gtg ccc atc ctg            96                                                                        Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gl - #y Val Val Pro Ile Leu                         20     - #             25     - #             30                   - - gtc gag ctg gac ggc gac gta aac ggc cac ag - #g ttc agc gtg tcc ggc           144                                                                        Val Glu Leu Asp Gly Asp Val Asn Gly His Ar - #g Phe Ser Val Ser Gly                     35         - #         40         - #         45                       - - gag ggc gag ggc gat gcc acc tac ggc aag ct - #g acc ctg aag ttc atc           192                                                                        Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Le - #u Thr Leu Lys Phe Ile                 50             - #     55             - #     60                           - - tgc acc acc ggc aag ctg ccc gtg ccc tgg cc - #c acc ctc gtg acc acc           240                                                                        Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pr - #o Thr Leu Val Thr Thr             65                 - # 70                 - # 75                 - # 80        - - ctg acc tgg ggc gtg cag tgc ttc agc cgc ta - #c ccc gac cac atg aag           288                                                                        Leu Thr Trp Gly Val Gln Cys Phe Ser Arg Ty - #r Pro Asp His Met Lys                             85 - #                 90 - #                 95               - - cag cac gac ttc ttc aag tcc gcc atg ccc ga - #a ggc tac gtc cag gag           336                                                                        Gln His Asp Phe Phe Lys Ser Ala Met Pro Gl - #u Gly Tyr Val Gln Glu                        100      - #           105      - #           110                   - - cgc acc atc ttc ttc aag gac gac ggc aac ta - #c aag acc cgc gcc gag           384                                                                        Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Ty - #r Lys Thr Arg Ala Glu                    115          - #       120          - #       125                       - - gtg aag ttc gag ggc gac acc ctg gtg aac cg - #c atc gag ctg aag ggc           432                                                                        Val Lys Phe Glu Gly Asp Thr Leu Val Asn Ar - #g Ile Glu Leu Lys Gly                130              - #   135              - #   140                           - - atc gac ttc aag gag gac ggc aac atc ctg gg - #g cac aag ctg gag tac           480                                                                        Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gl - #y His Lys Leu Glu Tyr            145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - aac tac atc agc cac aac gtc tat atc acc gc - #c gac aag cag aag         aac      528                                                                     Asn Tyr Ile Ser His Asn Val Tyr Ile Thr Al - #a Asp Lys Gln Lys Asn                           165  - #               170  - #               175               - - ggc atc aag gcc cac ttc aag atc cgc cac aa - #c atc gag gac ggc agc           576                                                                        Gly Ile Lys Ala His Phe Lys Ile Arg His As - #n Ile Glu Asp Gly Ser                        180      - #           185      - #           190                   - - gtg cag ctc gcc gac cac tac cag cag aac ac - #c ccc atc ggc gac ggc           624                                                                        Val Gln Leu Ala Asp His Tyr Gln Gln Asn Th - #r Pro Ile Gly Asp Gly                    195          - #       200          - #       205                       - - ccc gtg ctg ctg ccc gac aac cac tac ctg ag - #c acc cag tcc gcc ctg           672                                                                        Pro Val Leu Leu Pro Asp Asn His Tyr Leu Se - #r Thr Gln Ser Ala Leu                210              - #   215              - #   220                           - - agc aaa gac ccc aac gag aag cgc gat cac at - #g gtc ctg ctg gag ttc           720                                                                        Ser Lys Asp Pro Asn Glu Lys Arg Asp His Me - #t Val Leu Leu Glu Phe            225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - gtg acc gcc gcc ggg atc act ctc ggc atg ga - #c gag ctg tac aag               76 - #5                                                                   Val Thr Ala Ala Gly Ile Thr Leu Gly Met As - #p Glu Leu Tyr Lys                                245  - #               250  - #               255               - - taa                  - #                  - #                  - #                 768                                                                    - -  - - <210> SEQ ID NO 12                                                   <211> LENGTH: 255                                                              <212> TYPE: PRT                                                                <213> ORGANISM: Aequorea victoria                                               - - <400> SEQUENCE: 12                                                         - - Met Leu Ser Leu Arg Gln Ser Ile Arg Phe Ph - #e Lys Arg Ser Gly Ile        1               5  - #                10  - #                15                - - Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gl - #y Val Val Pro Ile Leu                   20      - #            25      - #            30                    - - Val Glu Leu Asp Gly Asp Val Asn Gly His Ar - #g Phe Ser Val Ser Gly               35          - #        40          - #        45                        - - Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Le - #u Thr Leu Lys Phe Ile           50              - #    55              - #    60                            - - Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pr - #o Thr Leu Val Thr Thr       65                  - #70                  - #75                  - #80         - - Leu Thr Trp Gly Val Gln Cys Phe Ser Arg Ty - #r Pro Asp His Met Lys                       85  - #                90  - #                95                - - Gln His Asp Phe Phe Lys Ser Ala Met Pro Gl - #u Gly Tyr Val Gln Glu                   100      - #           105      - #           110                   - - Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Ty - #r Lys Thr Arg Ala Glu               115          - #       120          - #       125                       - - Val Lys Phe Glu Gly Asp Thr Leu Val Asn Ar - #g Ile Glu Leu Lys Gly           130              - #   135              - #   140                           - - Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gl - #y His Lys Leu Glu Tyr       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Asn Tyr Ile Ser His Asn Val Tyr Ile Thr Al - #a Asp Lys Gln Lys         Asn                                                                                              165  - #               170  - #               175              - - Gly Ile Lys Ala His Phe Lys Ile Arg His As - #n Ile Glu Asp Gly Ser                   180      - #           185      - #           190                   - - Val Gln Leu Ala Asp His Tyr Gln Gln Asn Th - #r Pro Ile Gly Asp Gly               195          - #       200          - #       205                       - - Pro Val Leu Leu Pro Asp Asn His Tyr Leu Se - #r Thr Gln Ser Ala Leu           210              - #   215              - #   220                           - - Ser Lys Asp Pro Asn Glu Lys Arg Asp His Me - #t Val Leu Leu Glu Phe       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Val Thr Ala Ala Gly Ile Thr Leu Gly Met As - #p Glu Leu Tyr Lys                          245  - #               250  - #               255               - -  - - <210> SEQ ID NO 13                                                   <211> LENGTH: 768                                                              <212> TYPE: DNA                                                                <213> ORGANISM: Aequorea victoria                                              <220> FEATURE:                                                                 <221> NAME/KEY: CDS                                                            <222> LOCATION: (1)...(765)                                                    <223> OTHER INFORMATION: EYFP-mito                                              - - <400> SEQUENCE: 13                                                         - - atg ctg agc ctg cgc cag agc atc cgc ttc tt - #c aag cgc agc ggc atc            48                                                                        Met Leu Ser Leu Arg Gln Ser Ile Arg Phe Ph - #e Lys Arg Ser Gly Ile             1               5  - #                 10 - #                 15               - - atg gtg agc aag ggc gag gag ctg ttc acc gg - #g gtg gtg ccc atc ctg            96                                                                        Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gl - #y Val Val Pro Ile Leu                         20     - #             25     - #             30                   - - gtc gag ctg gac ggc gac gta aac ggc cac ag - #g ttc agc gtg tcc ggc           144                                                                        Val Glu Leu Asp Gly Asp Val Asn Gly His Ar - #g Phe Ser Val Ser Gly                     35         - #         40         - #         45                       - - gag ggc gag ggc gat gcc acc tac ggc aag ct - #g acc ctg aag ttc atc           192                                                                        Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Le - #u Thr Leu Lys Phe Ile                 50             - #     55             - #     60                           - - tgc acc acc ggc aag ctg ccc gtg ccc tgg cc - #c acc ctc gtg acc acc           240                                                                        Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pr - #o Thr Leu Val Thr Thr             65                 - # 70                 - # 75                 - # 80        - - ttc ggc tac ggc gtg cag tgc ttc gcc cgc ta - #c ccc gac cac atg aag           288                                                                        Phe Gly Tyr Gly Val Gln Cys Phe Ala Arg Ty - #r Pro Asp His Met Lys                             85 - #                 90 - #                 95               - - cag cac gac ttc ttc aag tcc gcc atg ccc ga - #a ggc tac gtc cag gag           336                                                                        Gln His Asp Phe Phe Lys Ser Ala Met Pro Gl - #u Gly Tyr Val Gln Glu                        100      - #           105      - #           110                   - - cgc acc atc ttc ttc aag gac gac ggc aac ta - #c aag acc cgc gcc gag           384                                                                        Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Ty - #r Lys Thr Arg Ala Glu                    115          - #       120          - #       125                       - - gtg aag ttc gag ggc gac acc ctg gtg aac cg - #c atc gag ctg aag ggc           432                                                                        Val Lys Phe Glu Gly Asp Thr Leu Val Asn Ar - #g Ile Glu Leu Lys Gly                130              - #   135              - #   140                           - - atc gac ttc aag gag gac ggc aac atc ctg gg - #g cac aag ctg gag tac           480                                                                        Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gl - #y His Lys Leu Glu Tyr            145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - aac tac aac agc cac aac gtc tat atc atg gc - #c gac aag cag aag         aac      528                                                                     Asn Tyr Asn Ser His Asn Val Tyr Ile Met Al - #a Asp Lys Gln Lys Asn                           165  - #               170  - #               175               - - ggc atc aag gtg aac ttc aag atc cgc cac aa - #c atc gag gac ggc agc           576                                                                        Gly Ile Lys Val Asn Phe Lys Ile Arg His As - #n Ile Glu Asp Gly Ser                        180      - #           185      - #           190                   - - gtg cag ctc gcc gac cac tac cag cag aac ac - #c ccc atc ggc gac ggc           624                                                                        Val Gln Leu Ala Asp His Tyr Gln Gln Asn Th - #r Pro Ile Gly Asp Gly                    195          - #       200          - #       205                       - - ccc gtg ctg ctg ccc gac aac cac tac ctg ag - #c tac cag tcc gcc ctg           672                                                                        Pro Val Leu Leu Pro Asp Asn His Tyr Leu Se - #r Tyr Gln Ser Ala Leu                210              - #   215              - #   220                           - - agc aaa gac ccc aac gag aag cgc gat cac at - #g gtc ctg ctg gag ttc           720                                                                        Ser Lys Asp Pro Asn Glu Lys Arg Asp His Me - #t Val Leu Leu Glu Phe            225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - gtg acc gcc gcc ggg atc act ctc ggc atg ga - #c gag ctg tac aag               76 - #5                                                                   Val Thr Ala Ala Gly Ile Thr Leu Gly Met As - #p Glu Leu Tyr Lys                                245  - #               250  - #               255               - - taa                  - #                  - #                  - #                 768                                                                    - -  - - <210> SEQ ID NO 14                                                   <211> LENGTH: 255                                                              <212> TYPE: PRT                                                                <213> ORGANISM: Aequorea victoria                                               - - <400> SEQUENCE: 14                                                         - - Met Leu Ser Leu Arg Gln Ser Ile Arg Phe Ph - #e Lys Arg Ser Gly Ile        1               5  - #                10  - #                15                - - Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gl - #y Val Val Pro Ile Leu                   20      - #            25      - #            30                    - - Val Glu Leu Asp Gly Asp Val Asn Gly His Ar - #g Phe Ser Val Ser Gly               35          - #        40          - #        45                        - - Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Le - #u Thr Leu Lys Phe Ile           50              - #    55              - #    60                            - - Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pr - #o Thr Leu Val Thr Thr       65                  - #70                  - #75                  - #80         - - Phe Gly Tyr Gly Val Gln Cys Phe Ala Arg Ty - #r Pro Asp His Met Lys                       85  - #                90  - #                95                - - Gln His Asp Phe Phe Lys Ser Ala Met Pro Gl - #u Gly Tyr Val Gln Glu                   100      - #           105      - #           110                   - - Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Ty - #r Lys Thr Arg Ala Glu               115          - #       120          - #       125                       - - Val Lys Phe Glu Gly Asp Thr Leu Val Asn Ar - #g Ile Glu Leu Lys Gly           130              - #   135              - #   140                           - - Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gl - #y His Lys Leu Glu Tyr       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Asn Tyr Asn Ser His Asn Val Tyr Ile Met Al - #a Asp Lys Gln Lys         Asn                                                                                              165  - #               170  - #               175              - - Gly Ile Lys Val Asn Phe Lys Ile Arg His As - #n Ile Glu Asp Gly Ser                   180      - #           185      - #           190                   - - Val Gln Leu Ala Asp His Tyr Gln Gln Asn Th - #r Pro Ile Gly Asp Gly               195          - #       200          - #       205                       - - Pro Val Leu Leu Pro Asp Asn His Tyr Leu Se - #r Tyr Gln Ser Ala Leu           210              - #   215              - #   220                           - - Ser Lys Asp Pro Asn Glu Lys Arg Asp His Me - #t Val Leu Leu Glu Phe       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Val Thr Ala Ala Gly Ile Thr Leu Gly Met As - #p Glu Leu Tyr Lys                          245  - #               250  - #               255               - -  - - <210> SEQ ID NO 15                                                   <211> LENGTH: 5                                                                <212> TYPE: PRT                                                                <213> ORGANISM: Homo sapiens                                                    - - <400> SEQUENCE: 15                                                         - - Lys Lys Lys Arg Lys                                                        1               5                                                              - -  - - <210> SEQ ID NO 16                                                   <211> LENGTH: 26                                                               <212> TYPE: PRT                                                                <213> ORGANISM: Homo sapiens                                                    - - <400> SEQUENCE: 16                                                         - - Met Leu Arg Thr Ser Ser Leu Phe Thr Arg Ar - #g Val Gln Pro Ser Leu        1               5  - #                10  - #                15                - - Phe Arg Asn Ile Leu Arg Leu Gln Ser Thr                                               20      - #            25                                           - -  - - <210> SEQ ID NO 17                                                   <211> LENGTH: 4                                                                <212> TYPE: PRT                                                                <213> ORGANISM: Homo sapiens                                                    - - <400> SEQUENCE: 17                                                         - - Lys Asp Glu Leu                                                           1                                                                               - -  - - <210> SEQ ID NO 18                                                   <211> LENGTH: 4                                                                <212> TYPE: PRT                                                                <213> ORGANISM: Aequorea victoria                                              <220> FEATURE:                                                                 <221> NAME/KEY: VARIANT                                                        <222> LOCATION: (0)...(0)                                                      <223> OTHER INFORMATION: Linker sequence                                        - - <400> SEQUENCE: 18                                                         - - Arg Ser Gly Ile                                                          __________________________________________________________________________ 

What is claimed is:
 1. A functional engineered fluorescent protein whose amino acid sequence comprises an amino acid sequence of Aequorea green fluorescent protein (SEQ ID NO: 2) containing substitutions selected from the group consisting of:S65G/S72A/T203Y/H231L in SEQ ID NO: 2; S65G/V68L/Q69K/S72A/T203Y/H231L in SEQ ID NO: 2; and K26R/F64L/S65T/Y66W/N146I/M153T/V163A/N164H/H231L in SEQ ID NO:
 2. 2. A method for determining the pH of a sample comprising:contacting the sample with an indicator comprising a first fluorescent protein moiety whose emission intensity changes as pH varies between pH 5 and 10, wherein said first fluorescent protein moiety comprises an Aequorea green fluorescent protein (SEQ ID NO: 2) containing substitutions selected from the group consisting of: S65G/S72A/T203Y/H231L in SEQ ID NO: 2; S65G/V68L/Q69K/S72A/T203Y/H231L in SEQ ID NO: 2; and K26R/F64L/S65T/Y66W/N146I/M153T/V163A/N164H/H231L in SEQ ID NO: 2; exciting the indicator; and determining the intensity of light emitted by the first fluorescent protein moiety at a first wavelength, wherein the emission intensity of the first fluorescent protein moiety indicates the pH of the sample.
 3. The method of claim 2, wherein the sample is a biological tissue.
 4. The method of claim 2, wherein the sample is a cell or a region thereof.
 5. The method of claim 2, further comprising contacting the sample with a second fluorescent protein moiety whose emission intensity changes as pH varies from 5 to 10, wherein the second fluorescent protein moiety emits at a second wavelength that is distinct from the first wavelength and wherein said second fluorescent protein moiety comprises an Aequorea green fluorescent protein (SEQ ID NO:2) containing substitutions selected from the group consisting of:S65G/S72A/T203Y/H231L in SEQ ID NO:2; S65G/V68L/Q69K/S72A/T203Y/H231L in SEQ ID NO:2; and K26R/F64L/S65T/Y66W/N1461I/M153T/V163A/N164H/H231L in SEQ ID NO:2; exciting the second protein moiety; determining the intensity of light emitted by the second protein moiety at the second wavelength; and comparing the fluorescence at the second wavelength to the fluorescence at the first wavelength.
 6. The method of claim 2, wherein the first fluorescent protein moiety is linked to a targeting sequence.
 7. The method of claim 6, wherein the targeting sequence directs the first fluorescent protein moiety to a region of a cell.
 8. The method of claim 7, wherein the region of the cell is the cytosol, the endoplasmic reticulum, the mitochondrial matrix, the chloroplast lumen, the medial trans-Golgi cisternae, the lumen of lysosome, or the lumen of an endosome.
 9. The method of claim 8, wherein the targeting sequence comprises the amino terminal 81 amino acids of human type II membrane-anchored protein galactosyltransferase.
 10. The method of claim 8, wherein the targeting sequence comprises the amino terminal 12 amino acids of the presequence of subunit IV of cytochrome c oxidase.
 11. The method of claim 10, wherein the targeting sequence further comprises the sequence Arg-Ser-Gly-Ile (SEQ ID NO: 18).
 12. The method of claim 6, wherein the targeting sequence causes the first fluorescent protein moiety to be secreted from the cell.
 13. The method of claim 2, wherein the first fluorescent protein moiety has a pKa greater than 6.1.
 14. The method of claim 2, wherein the first fluorescent protein moiety has a pKa greater than 6.3.
 15. The method of claim 2, wherein the first fluorescent protein moiety has a pKa greater than 6.9.
 16. A kit useful for the detection of the pH in a sample, the kit comprising carrier means containing one or more containers comprising a first container containing a functional engineered fluorescent protein whose amino acid sequence is an amino acid sequence of Aequorea green fluorescent protein (SEQ ID NO: 2) containing substitutions selected from the group consisting of:S65G/S72A/T203Y/H231L in SEQ ID NO: 2; S65G/V68L/Q69K/S72A/T203Y/H231L in SEQ ID NO: 2; and K26R/F64L/S65T/Y66W/N146I/M153T/V163A/N164H/H231L in SEQ ID NO:
 2. 